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ABSTRACT
Approximately 20% of Canadian adults currently smoke, despite widespread
knowledge of the significant health problems associated with tobacco use. Of the many
smoking cessation interventions developed, contingency management (CM) appears to be
among the most efficacious. This type of external motivation has previously been shown
to be very efficacious when the contingency is in place, but its effects tend to diminish
once the contingency is removed. In contrast, motivational interviewing (MI) is designed
to increase an individual's internal motivation for behaviour change. Studies have shown
this type of intervention to produce modest effects for smoking cessation, although
follow-up data suggest that the effects of such interventions can be relatively longlasting.
This study evaluated the combined efficacy of CM and a brief computer-delivered
motivational intervention (CDMI) for smoking cessation. This CDMI is based on the
principles of MI but is modified from this traditional approach in order to accommodate a
computerized delivery of the intervention. The intention was to harness the short-term
effectiveness of CM while enhancing or perhaps extending its effects by combining it
with CDMI. Using a sample of 48 opiate-dependent persons receiving methadone
maintenance therapy, this randomized trial compared rates of smoking cessation for
patients receiving CDMI and CM together to those of patients receiving CDMI alone or
treatment as usual.
Results indicated that the combination of CDMI and CM was most effective at
producing reductions in breath carbon monoxide during the four-week study period,
while CDMI only participants endorsed the highest levels of motivation to quit smoking.

V

At five-week follow-up, CDMI only participants continued to show reductions in number
of cigarettes smoked, while CDMI plus CM participants increased their use of cigarettes
relative to when the intervention was in place. These results are discussed with respect to
the Self-Determination Theory and are used to suggest directions for future research and
larger scale studies.
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Chapter I
INTRODUCTION
Introduction
Smoking is the most preventable cause of death and disease in the United States and
Canada. Each year, tobacco is responsible for over 438,000 (or about one in five) deaths
in the United States alone (Centers for Disease Control and Prevention, 2005). Although
smoking prevalence rates have dropped over the past two decades, current estimates
suggest that 20% of Canadians smoke cigarettes (Health Canada, 2006).
There are a wide variety of interventions designed to reduce tobacco use.
Systematic reviews support the efficacy of nicotine replacement therapy (Silagy,
Lancaster, Stead, Mant, & Fowler, 2006), individual behavioural counselling (Lancaster
& Stead, 2006a), treatment with the antidepressants bupropion and nortriptyline (Hughes,
Stead, & Lancaster, 2006a), and especially varenicline (e.g., Jorenby et al., 2006). In each
case, these interventions have been found to be 1.5 times more effective relative to notreatment groups. Less effective but still promising treatments include self-help materials
(Lancaster & Stead, 2006b), quit and win contests (Hey & Perera, 2006a), and group
therapy (Stead & Lancaster, 2006). There is currently very little evidence to support other
interventions such as relapse prevention (Hajek, Stead, West, Jarvis, & Lancaster, 2006),
exercise programs (Ussher, 2006), anxiolytics (Hughes, Stead, & Lancaster, 2006b), and
acupuncture or laser therapy (White, Rampes, & Campbell, 2006).
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Contingency Management
Contingency management (CM) has been shown to have powerful short-term
effects on smoking. CM provides an external motivation for behaviour change following
the principles of behaviour therapy (itself a product of operant conditioning research).
When the target behaviour (e.g., tobacco abstinence) is observed, the individual is
reinforced, often with a token or voucher exchangeable for retail goods. When the
behaviour is not observed, no reward is provided (Petry & Simcic, 2002). Although
decades of research have demonstrated the efficacy of CM in treating substance abuse
(Higgins & Silverman, 1999), CM is often criticized because the reinforced behaviours
tend to diminish or extinguish when the contingency is removed (Petry, 2000). Reviews
of this research confirm that these incentives enhance short-term cessation rates, but the
gains tend to dissipate once the rewards are no longer available (Hey & Perera, 2006b;
Prendergast, Podus, Finney, Greenwell, & Roll, 2006).
Two recent meta-analyses suggest that CM for substance use produces moderate
effect sizes, with one study reporting an average effect size of r = .32 (Lussier, Heil,
Mongeon, Badger, & Higgins, 2006) and the second reporting an average effect of d =
.42 (Prendergast et al., 2006). These effects were found to be larger when the delivery of
the contingency was immediate, the monetary value of the contingency was high (Lussier
et al., 2006), and the treatment duration was relatively brief (Prendergast et al., 2006).
With respect to smoking cessation, CM appears to be remarkably efficacious as
an intervention (e.g., Heil, Tidey, Holmes, Badger, & Higgins, 2003; Rand, Stitzer,
Bigelow, & Mead, 1989; Stitzer & Bigelow, 1985). However, long-term follow-up data
suggest that CM only delays relapse to smoking, and does not reduce smoking levels
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relative to baseline (Rand et al., 1989). In general, results for CM are less durable than
those for most approaches, as the CM intervention is most effective when the
contingency is in place.

Motivational interviewing
Motivational interviewing (MI) has been shown to have more lasting effects on
behaviour change. Broadly, MI is a client-centred counselling method designed to
enhance an individual's motivation for behaviour change (Miller & Mount, 2001). This is
done through reflective listening and a directive but non-confrontational approach. MI is
typically a brief intervention that includes assessment of problem behaviours,
personalized feedback, exploration of ambivalence regarding change, and elicitation of
the patient's own reasons for possibly wanting to change (Miller & Rollnick, 1991).
Several meta-analyses support a number of conclusions regarding MI. First, MI is
effective at producing change across a wide variety of behaviours, ranging from diet and
exercise to substance abuse. Although effect sizes vary, MI tends to produce moderate
effects in the range of .35 to .56 relative to no-treatment comparisons (Burke, Dunn,
Atkins, & Phelps, 2004). Second, MI often works as well as longer interventions (Burke
et al., 2004). For example, in one meta-analysis, MI was found to be as efficacious as
alternative treatments, despite being shorter than comparison treatments by an average of
180 minutes (Burke, Arkowitz, & Menchola, 2003). Third, MI appears to be most
effective when used as an enhancement to other treatments (Burke et al., 2003; Dunn,
Deroo, & Rivara, 2001). Fourth, MI may be most effective with individuals who are more
angry/resistant and less ready to change (Burke et al., 2004; Heather, Rollnick, Bell, &
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Richmond, 1996; Project MATCH Research Group, 1997), and MI may be
contraindicated for individuals who are already committed to behaviour change
(Hettema, Steel, & Miller, 2005). There is also some evidence to suggest that the effects
of MI are larger for minority samples (Hettema et al., 2005).
With respect to follow-up data, MI appears to produce lasting effects. Dunn et al.
(2001) found evidence to suggest that the effects of MI remain the same regardless of the
length of time of the follow-up. Similarly, Burke et al. (2003) found that across several
studies, the effect sizes at 20 weeks follow-up were not significantly different than effect
sizes at 67 weeks follow-up. This is consistent with other meta-analytic reviews that have
shown that brief MI for alcohol abuse can lead to reductions in drinking six to 12 months
after the intervention (Wilk, Jensen, & Havighurst, 1997).
MI targeting smoking cessation tends to produce smaller effects than MI targeting
other substances of abuse. Recent meta-analyses estimate the effect size for such
interventions, relative to a no treatment/placebo condition, to range from . 11 (Burke et
al., 2003; Burke et al., 2004) to .14 (Hettema et al., 2005). However, these small effect
sizes are comparable to those for most other smoking cessation interventions (Lancaster
& Stead, 2006a), for which statistical significance is often only obtainable in very highly
powered studies. The relatively weak effect of MI for smoking cessation may also be a
result of the disordinal efficacy of MI noted earlier: MI may in fact be ineffective or even
deleterious with many of the more highly motivated individuals who smoke, but quite
efficacious with those less motivated. The strong effects of interventions using the 5 As
approach (^4sk about smoking status, Advise to quit smoking, Assess interest in quitting,
Assist in quitting, Arrange Follow-up; e.g. Fiore et al., 2000; Pbert et al., 2004), which
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presents motivational techniques to those less motivated and problem solving/goal setting
to those with more motivation, supports this suggestion.

Computerized interventions
One innovative method of delivering interventions such as MI has been through
computerized programs. Computerized interventions offer many advantages over
traditional interventions, such as the limited time commitment required from health care
providers, the minimal costs associated with their use, the ability of users to maintain
their anonymity, and the intervention's potential accessibility (Copeland & Martin,
2004). Because of this accessibility, these computerized approaches offer the possibility
of reaching a large group of people regardless of their age, gender, or socio-economic
status. This also includes individuals who may not otherwise receive support for their quit
attempt or who may not have been considering reducing their substance use (Ondersma,
Chase, Svikis, & Schuster, 2005).
Computer-based interventions using such change strategies as psychoeducation,
cognitive restructuring, relapse prevention, and behavioural self-control training have
previously been developed. These interventions address a wide variety of mental health
problems, such as depression and anxiety disorders (e.g., Carlbring, Westling,
Ljungstrand, Ekselius, & Andersson, 2001; Christensen, Griffiths, & Korten, 2002;
Lange, van de Ven, Schrieken, & Emmelkamp, 2001) as well as behavioural health
problems such as obesity (Tate, Wing, & Winett, 2001). These computerized
interventions have also been shown to be effective for reducing alcohol (Hester &
Delaney, 1997), drug (Ondersma et al., 2005), and tobacco (Schneider, Walter, &
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O'Donnell, 1990) use. One study has shown brief computerized interventions to reduce
hazardous drinking at rates similar to practitioner-delivered interventions (Kypri et al.,
2004).

Smoking and methadone maintenance
Smoking rates are particularly high among substance abusers. Over 90% of
individuals in inpatient treatment for alcohol dependence have been found to smoke
cigarettes (Bien & Burge, 1990), and rates ranging from 74% to 88% have been reported
for individuals in treatment for drug dependence (Kalman, 1998). In particular, opiate
users in treatment have among the highest smoking rates in the US population (Stein &
Anderson, 2003). Amongst methadone-maintained individuals, smoking prevalence rates
of 85% to 100% have been reported (Best et al., 1998; Chait & Griffiths, 1984;
Clemmey, Brooner, Chutuape, Kidorf, & Stitzer, 1997; Stark & Campbell, 1993).
The most common and efficacious treatment for opiate dependence is methadone
maintenance therapy. Methadone is a medication used for the past 40 years in the
treatment of heroin addiction. It acts by occupying the opiate receptor and blocking the
"high" that comes from heroin use. Methadone also eliminates withdrawal symptoms and
craving for heroin (Zickler, 1999). In Canada, the number of individuals receiving
methadone maintenance therapy is growing, with an almost five-fold increase in Ontario
alone between 1996 and 2001 (Strike, Urbanoski, Fischer, Marsh, & Millson, 2005). The
high rate of smoking prevalence, coupled with the daily dispensing of methadone,
presents a unique opportunity for implementing smoking cessation programs with opiatedependent individuals in treatment.
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Given the high rates of tobacco use in methadone-maintained individuals, several
authors have suggested that more needs to be done to address smoking in this population
(e.g., Olsen, Alford, Horton, & Saitz, 2005; Richter & Ahluwalia, 2000; Richter, Choi,
McCool, Harris, & Ahluwalia, 2004). Despite this, relatively few smoking intervention
studies have been designed for those in methadone treatment. Although a limited number
of approaches have been studied to date, CM or MI have been included as interventions
in each of these studies.

Contingency management with methadone-maintained individuals
A number of studies have utilized CM within methadone-maintained samples. In
one example of a CM approach, 17 methadone-maintained smokers were followed over a
four-week period (Shoptaw, Jarvik, Ling, & Rawson, 1996). As part of the CM, breath
carbon monoxide (CO) was assessed three times a week. For each sample that indicated
recent abstinence from smoking, participants were given vouchers that could be
exchanged for merchandise at the end of the study. These vouchers increased in value for
each consecutive day of smoking abstinence. During the CM period, breath CO levels
were significantly reduced (indicating less smoking) relative to baseline. Almost one in
four participants (23.4%) were able to maintain at least one week of continuous smoking
abstinence. Although these results appear promising, all patients had resumed smoking
by the end of the study. Breath CO levels did suggest, however, that they had reduced
their cigarette smoking relative to baseline.
Researchers have also studied the effects of CM as part of more comprehensive
smoking cessation programs. This line of study shows some support for its short-term
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effectiveness above and beyond other approaches. Shoptaw et al. (2002) compared the
efficacy of relapse prevention and CM (alone and in combination) for individuals
receiving nicotine replacement therapy. A total of 175 methadone-maintained individuals
were placed into one of four conditions: 1) nicotine replacement therapy only (control
condition); 2) relapse prevention and nicotine replacement therapy; 3) CM and nicotine
replacement therapy; and 4) relapse prevention, CM, and nicotine replacement therapy.
During the 12-week study period, participants provided thrice weekly samples of breath
CO, urine (tested for opiate and cocaine use), and self-reports on the number of cigarettes
smoked. Participants were found to provide more opiate- and cocaine-free urines on the
weeks that they met criteria for smoking abstinence. In terms of the effectiveness of the
intervention on smoking, participants who received CM showed higher rates of smoking
abstinence during the study period. No effect was found for those receiving relapse
prevention alone. However, the gains made by the CM groups were not maintained at sixand 12- month follow-up.
Therefore, just as with CM interventions for smoking cessation in the general
population, CM with methadone maintained individuals appears to result in significant
but short-lasting reductions in smoking behaviour.

Motivational interviewing with methadone-maintained individuals
Only one smoking intervention study using MI with methadone maintained
individuals has been found. Haug, Svikis, and DiClemente (2004) studied 63 pregnant,
methadone-maintained smokers. All participants received smoking cessation advice from
health practitioners, as well as printed material regarding the harmful effects of smoking
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during pregnancy. Half of the women also received four individual sessions of MI. At
ten-week follow-up, no difference in smoking (via self-report, urine cotinine, or breath
CO) was found between the MI group and the standard care group. However, women
who received the MI were more likely to have increased their motivation to change,
while the standard care group endorsed less motivation relative to the start of the study
period.
Other research suggests that methadone-maintained individuals respond well to
motivational strategies when the intervention targets opiate use (Saunders, Wilkinson, &
Phillips, 1995). A total of 57 methadone maintained patients received one hour of MI
regarding their opiate use. They were compared to a group (N= 65) that received an
educational procedure (consisting of a presentation and discussion) on the physical
effects of opiate use, brief advice on how to stop, and referral information. At the sixmonth follow-up, those who received the MI showed greater commitment to opiate
abstinence and fewer opiate-related problems. The MI group also remained in methadone
treatment longer, and for those who did relapse to opiates, it took them longer to relapse
than the educational group. Saunders et al. (1995) found that after just one hour of MI,
lasting effects on opiate use could be seen six months later. This supports a recent
systematic review that suggests that brief interventions for smoking are just as effective
as more intensive counselling methods (Lancaster & Stead, 2006a).
There is therefore some indication that MI with methadone-maintained
individuals leads to longer-term gains relative to standard care or educational
interventions. These effects may be seen after even very brief interventions.
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First research objective: Combined intervention effects
This study intends to build on this previous research in several ways. First, it
examines the efficacy of a combined intervention that aims to increase internal
motivation (via a brief computer-delivered motivational-based intervention [CDMI])
while also building external motivation (via CM). The intent is to harness CM's powerful
short-term effects while also engaging the potentially longer-term effects of the CDMI.
This CDMI is based on the principles of MI, and is superficially very much like a
typical MI session. However, MI by definition is a highly empathic interpersonal process;
the CDMI thus cannot be properly understood as MI. It is more accurate to say that it is a
motivational intervention.

Theory behind combined interventions
Self-determination theory (SDT; Deci & Ryan, 1985) is helpful in guiding
hypotheses for this combined intervention group. SDT is a theory of motivation that
addresses the degree to which human behaviours are self-determined and involve free
choice. This theory developed in part out of the investigation of the effects of external
rewards on internal motivation. In recent years it has been used as a theoretical
framework for understanding the efficacy of motivational interventions (i.e., Markland,
Ryan, Tobin, & Rollnick, 2005; Vansteenkiste & Sheldon, 2006).
SDT posits that behaviour can be understood in terms of a continuum of
autonomy (Ryan & Deci, 2000). At the far left of the continuum is amotivation, which
occurs when an individual does not act at all, or acts without intent (e.g., "going through
the motions"). Further up the continuum is extrinsically motivated behaviour, which is
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thought to have four levels, with the degree of extrinsic motivation decreasing as they
progress. The first, external regulation, describes actions done in order to satisfy an
external demand or receive a reward. Introjected regulation describes behaviours
designed to avoid guilt or anxiety. Individuals are thought to evidence identified
regulation when they participate in a behaviour because they value a goal and feel it to be
personally important. The last stage of extrinsic motivation is integrated motivation. This
occurs when one acts in line with their values and needs. In this type of extrinsically
motivated behaviour, actions are designed to attain desired outcomes rather than for
inherent enjoyment. At the far right of the continuum is intrinsic regulation. Behaviours
at this end of the continuum are intrinsically motivated and are done because they bring
inherent enjoyment or satisfaction. The perceived locus of causality for behaviours along
this continuum progresses from impersonal (at the amotivated end), through various
levels of external causality (for extrinsically motivated behaviours) to internal causality
(for intrinsically motivated behaviours).
The SDT posits that the stability of behaviours is closely related to where they fall
on this continuum, such that behaviour based on amotivation or perceived external
controls will temporarily be compliant so long as these controls are in place, whereas
intrinsically motivated changes will be stable and persistent. Available evidence supports
this aspect of SDT. For example, lasting behavioural changes such as long-term weight
loss (Williams, Grow, Freedman, Ryan, & Deci, 1996) and diabetes management
(Williams, McGregor, Zeldman, Freedman, & Deci, 2004), have both been associated
with more autonomous and intrinsically motivated reasons for participating in treatment.
A high degree of perceived autonomy and internalized motives for behavioural change

have also been associated with better adherence outcomes in methadone maintenance
therapy (Zeldman, Ryan, & Fiscella, 2004). This same study showed that a high degree of
external motivation was associated with higher rates of treatment non-compliance.
SDT, then, would predict that CDMI will lead to better outcomes at follow-up
relative to control, as motivational interventions are intended to promote autonomous
motivation for change. The predicted outcome for the CDMI plus CM group was less
clear. In the case of this combined intervention group, studies examining the effect of
adding extrinsic rewards (i.e., externally rewarding) to intrinsically motivating (i.e.,
inherently rewarding) activities were helpful in guiding hypotheses.
Participants in one study completed puzzles that were found to be highly
intrinsically motivating. The experimental group received $1 for each puzzle that was
completed while the control group received no contingent payments. Results indicated
that solving the puzzles for money led to decreases in intrinsic motivation relative to
controls (Deci, 1971). A second study paid college newspaper staff 50 cents for each
headline written (an intrinsically rewarding activity). Results found, relative to controls
who received no additional payments, a decrease in intrinsic motivation that lasted as
long as eight weeks after the contingencies were removed (Deci, 1971). These studies
indicate that extrinsic rewards can have deleterious effects on intrinsic motivation. This is
because these extrinsic rewards (such as money) are thought to change the perceived
locus of control from internal to external, resulting in decreased intrinsic motivation
(Deci & Ryan, 1985). A meta-analysis of all available experiments such as these has
found that tangible rewards contingent upon task performance undermine intrinsic
motivation (Deci, Koestner, & Ryan, 1999).
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Although smoking cessation is not intrinsically rewarding, these results were used
to hypothesize that the combination of CDMI and monetary rewards (i.e., CM) will
decrease intrinsic motivation for change and thereby interfere with the processes of
CDMI. It is expected that the lack of autonomy support (considered to be a key
component of self-determined behaviour; Deci, 1975) in the CM used in this study will
also interfere with the process of self-motivation. It is further hypothesized, based on the
large body of evidence for the short-term efficacy of CM, that reductions in smoking
behaviour will be observed while the contingency phase is in place. However, the work
of Deci (1971) suggests that this combined group will evidence higher rates of smoking
at follow-up than individuals who received only the CDMI.

Previous research on combined interventions
Only two found studies examined the combination of motivational enhancement
and contingency management. In both studies, motivation enhancement referred to a
relatively brief intervention that used the techniques of MI to promote behaviour change.
Budney, Higgins, Radonovich, and Novy (2000) assigned 60 individuals seeking
outpatient treatment for marijuana dependence to one of three conditions: 1) motivational
enhancement alone (four one-hour sessions); 2) motivational enhancement and
behavioural coping skills therapy (14 hour-long sessions); or 3) motivational
enhancement and behavioural coping skills therapy plus CM (14 one-hour sessions).
Contingencies were provided for marijuana-negative urine drug screens in the amount of
$1.50 worth of vouchers for the first negative sample, increasing by $1.50 for each
subsequent sample in a row. Budney et al. (2000) found that the motivational
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enhancement and behavioural coping skills plus CM group had significantly greater
durations of marijuana abstinence than the other two groups, as well as a larger
percentage of participants that were marijuana abstinent at the end of the study period.
No difference was found between the motivational enhancement alone and motivational
enhancement plus behavioural coping skills group.
A second study built on the work of Budney et al. (2000) by adding a control
condition and conducting follow-up assessment. In this study, 240 marijuana dependent
participants were randomly assigned to one of four study conditions: 1) motivational
enhancement plus cognitive behavioural therapy (nine one-hour sessions); 2) CM only; 3)
motivational enhancement and cognitive behaviour therapy plus CM (nine one-hour
sessions); and 4) control (Kadden, Litt, Kabela-Cormier, & Petry, 2007). In this study,
vouchers were provided for marijuana-free urine drug screens that started at $10 for the
first negative sample, and totalled $385 if all samples were negative. Follow-up was
collected at post-treatment and at three-month intervals for one year. Kadden et al. (2007)
found that the two CM groups had the best outcomes, however the CM only group had
highest abstinence rates post-treatment, while the CM combined with motivational
enhancement and cognitive behaviour therapy had the highest abstinence rates during the
follow-up assessments. Despite the findings that MI has been shown to have relatively
lasting effects on behaviour change (e.g., Project MATCH Research Group, 1997;
Saunders et al., 1995), Kadden et al. (2007) suggest that the cognitive behavioural
component of this combined intervention led to the higher rates of abstinence over the
follow-up period. However, this remains speculation, as the relative contributions of the
three interventions cannot be determined.
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While Budney et al. (2000) and Kadden et al. (2007) were able to demonstrate the
relative efficacy of a group that received both motivational enhancement and CM, in both
studies these were combined with a third intervention. The addition of behavioural skills
coping or cognitive behavioural therapy to the motivational enhancement and CM
intervention does clearly demonstrate which of these three interventions (or combination
of interventions) produced the larger effects.
Therefore, this study aims to extend the earlier research by Budney et al. (2000)
and Kadden et al. (2007) by examining the combination of only two interventions: CM
and motivational intervention. This is expected to help further dismantle the treatment
effects demonstrated by these two studies. The current study also aims to extend this
approach to the treatment of nicotine dependence.

Second research objective: Computerized intervention for nicotine dependence
In examining this first research objective, the proposed study develops and utilizes a
brief motivational-based computerized intervention targeting nicotine dependence
(CDMI). It is therefore a secondary goal to evaluate the efficacy of this novel treatmentdelivery approach.
The intervention used in this study is a motivational-based intervention similar to
the one developed by Ondersma et al. (2005) in their study of drug-abusing post-partum
women. Ondersma et al. (2005) found that relative to baseline, participants endorsed
significantly higher levels of motivation to change their drug use following one session of
CDMI. A one-month follow-up found an intervention effect of .49 (Cohen's d). The
women also rated the intervention as highly satisfactory, easy to use, and respectful. A
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larger scale study with 107 drug-abusing post-partum women found an odds ratio of 2.48,
indicating that women who received the one session of CDMI were less likely to use
illicit drugs at four-month follow-up relative to controls (Ondersma, Svikis, & Schuster,
2007). These findings provide preliminary evidence that a computerized motivational
intervention is effective in increasing motivation to change addictive behaviours.
Once computer-based brief interventions such as that utilized in the current study
are developed and evaluated, the way is paved for more widespread use. This flexible
intervention can easily be modified (at minimal cost) so that it may be implemented in
standard outpatient mental health clinics, substance abuse treatment programs, or
physician's offices. It could also potentially lead to an internet-based intervention that
may be accessed by an even larger number of people world-wide. The development and
utilization of such programs may lead to large population effects and may have a
significant impact on overall rates of smoking cessation.

Summary
This research therefore aims to examine the efficacy of a combined intervention
of CDMI and CM relative to a control group and to CDMI alone. Primary outcomes
include changes in smoking behaviour and in motivation to quit smoking. Motivation is a
necessary factor in sustaining behaviour change, and CDMI is expected to primarily have
an effect on smoking cessation by increasing this motivation to change. A secondary goal
of this research is to develop a brief computer-delivered motivational intervention
(CDMI) targeting smoking cessation. This approach offers many potential advantages
over traditional MI, and previous work by Ondersma et al. (2005) and Ondersma et al.,

17
(2007) has shown similar computerized interventions to be effective at reducing drug use
amongst post-partum women.
Following the stage model of intervention development (Rounsaville, Carroll, &
Onken, 2001), this investigation is conceptualized as a Stage la/lb exploratory study. In
this model, Stage I studies are designed to develop new intervention approaches, establish
feasibility and acceptability, and estimate effect size. Stage I studies provide the basis for
Stage II studies in which efficacy is established in an adequately powered clinical trial.
Stage I studies are by definition not fully powered trials, but instead focus on the Stage I
goals of acceptability, feasibility, and effect-size estimation.
These hypotheses for this study are largely derived from SDT, which posits that
behavioural change should be most apparent in the short term for individuals
experiencing external motivation to change. Individuals experiencing internal motivation
to change should evidence growing levels of motivation but not immediate reductions in
smoking behaviour. We therefore predict differences in smoking behaviour and levels of
motivation (during the study period and at follow-up) between the CDMI only and CDMI
plus CM groups. The four primary hypotheses are: 1) At post-treatment and at five week
follow-up, rates of smoking (as measured by breath carbon monoxide, saliva cotinine,
and number of self-reported cigarettes smoked) will be lower in the two treatment groups
(CDMI and CDMI plus CM) than in the control group; 2) At post-treatment, rates of
smoking will be lower in the combined intervention (CDMI plus CM) than in the CDMI
alone condition; 3) At follow-up, rates of smoking will be lower in the CDMI alone
condition relative to CDMI plus CM; and 4) levels of self-reported motivation will be
highest for the CDMI only group at post-study and at follow-up.
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Chapter II
METHOD
Participants
All participants in this study were enrolled in methadone maintenance treatment at a
clinic in Detroit, Michigan. Consistent with other smoking cessation studies, participants
in this study had to report smoking ten or more tobacco cigarettes on an average day
(Frosch, Shoptaw, Nahom, & Jarvik, 2000; Schmitz, Rhoades, & Grabowski, 1995;
Shoptaw et al., 1996; Stein & Anderson, 2003). Potential participants also had to attend
the clinic on Mondays, Wednesdays, and Fridays, as these were the days that samples
were taken. Potential participants were excluded from the study if they were currently
taking the medication bupropion (Wellbutrin/Zyban), as this is an antidepressant
medication that is also an effective smoking cessation aid.
A total of 48 participants (16 in each group) met the above criteria and were
enrolled in the study. Completion rates (defined as individuals still providing data at the
end of the five week study period) were 87.5% (N=14) in the control group; 68.8%
(N=l 1) in the CDMI only group; and 75% (N=12) in the CDMI plus CM group. Reasons
for non-completion were that the participant left the clinic (N=4); the participant failed to
meet regularly with the researcher (N=4); or that the participant asked to withdraw from
the study (N=3). No significant pattern to non-completion was found across the three
groups. Data analysis was conducted only on completers.
Participants tended to be middle-aged (M= 50 years, range = 26 to 66), female
(65%), and African American (81%). The modal level of education was General
Educational Development (GED; High School equivalent) level, with 14% having
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completed less than Grade 10 and 22% having some college or university. With respect
to socioeconomic status, 84% of the sample was unemployed and 49% had an income of
less than $500 per month.
The average participant had a long history of cigarette use (M= 30 years; range = 5
to 50 years). Participants had tried to quit an average of six times in their life, and
currently smoked a mean of 15 cigarettes per day. Rates of illicit drug use were also high
in this sample, as urine drug screens in the five weeks prior to the study were frequently
positive for cocaine and opiates (43% and 34% of the samples, respectively).

Procedure
All procedures used in this study were approved by the University of Windsor's
Research Ethics Board (Appendix A) and Wayne State University's Human Investigation
Committee (Appendix B). Potential participants were approached in the clinic waiting
area and asked to complete a brief questionnaire related to their use of tobacco (Appendix
C). The investigator explained that by completing this questionnaire, they might be
contacted about a research study where they had the opportunity to earn $70 or more in
gift cards. Screened individuals earned a $1 gift certificate (see Appendix D for study
expenses). McDonald's and Target gift certificates were used throughout this study.
To maintain confidentiality while ensuring the ability to match responses to
particular participants, all questionnaires were assigned a unique participant code.

Baseline
Participants provided consent to participate in the study (Appendix E) and were
then provided with a list of stop smoking resources (both phone and internet-based;
Appendix F). This assured that all participants, including those in the control condition,
had support available to them for any quit attempt they chose to make. Participants were
then randomly assigned to one of the three study groups using a modified matched-pairs
approach to ensure group equivalence on gender and ethnicity. Matching the groups on
major demographic criteria allows for a maximal ability to speculate on any differential
effects of the interventions. In particular, groups were matched on ethnicity because of
previous findings that the effects of MI are larger for minority samples (Hettema et al.,
2005).
Following the receipt of informed consent and random assignment to the study
condition, the investigator introduced the participant to the computer, which was used to
gather all background information and to administer all baseline questionnaires other than
the Timeline Followback (a measure used to assess number of cigarettes smoked in the
past thirty days), which was completed by hand (see Table 1 for timeline of measures
administered throughout the study). Participants were given the choice between using a
mouse or touch-screen system. Participants received a $5 gift certificate for completing
these initial questionnaires (see Appendix G for the timeline of payments throughout the
study).
Across all three groups, the first week of the study was the baseline period. The
purpose of this baseline was to record the participants' level of smoking prior to the

Table 1

Timeline of measures.
Baseline

Background Measures

Week 2

Week 3

Week 4

Post-study

Follow-up

X

Intervention

X

Primary Measures
Biological indicators
Breath CO

3x

3x

3x

3x

X

Saliva Cotinine

lx

lx

lx

lx

X

Self-reported cigarette use
Timelime Followback
Brief Tobacco Quantity
Assessment

X

X

3x

3x

3x

3x

3x

3x

3x

3x

Motivation
Tobacco Use and Beliefs
Measure

X

to

Table 1 (continued)

Timeline of measures.
Baseline

Secondary Measures
Fagerstrom Test for Nicotine
Dependence

X

Smoking Self-Efficacy
Questionnaire

X

Readiness to Change

X

Questionnaire
Stages of Change Algorithm

X

Negative Effects of Smoking
Control Group
Intervention Groups
Attributes of Treatment
Measure
Motivation for Change
Questionnaire

X

Table 1 (continued)

Timeline of measures.
Baseline

Week 2

Week 3

Week 4

Post-study

X

Treatment Self-Regulation
Questionnaire
Illicit drug use

Week 1

X

X

Follow-up

intervention, as this afforded the ability to test for within-subject effects. During this
baseline, participants were asked to provide a breath CO reading and complete (by hand)
the Tobacco Use and Beliefs Measure (used to assess motivation to quit and confidence
in ability to quit) and the Brief Tobacco Quantity Assessment (used to assess number of
cigarettes smoked in the past several days) on three occasions (Monday, Wednesday, and
Friday). Saliva cotinine was also randomly collected on one of these days. During the
baseline period, all participants were compensated with $2 in gift certificates each time
they provided a breath CO sample and completed the brief measures.

Intervention
Following the one-week baseline period, the CDMI only and CDMI plus CM
groups underwent the first of two computerized CDMI sessions (Appendix H).
Individuals in the control condition interacted with the computer on a non-smoking
related task (Appendix I). The fact that all participants interacted with the computer
helped control for any computer-related effects.
The intervention lasted approximately 20 minutes and was individually tailored to
each participant. It consisted of three main components:

1) Pros and cons of tobacco use, in which the participant chose from a list of options the
positive and negative aspects of tobacco use for them (e.g., "Smoking helps me relax and
deal with stress", "Smoking helps me lose weight or maintain my current weight",
"Smoking increases my risk of cancer and other diseases", "Smoking makes my face and
body look older", see Figure 1).
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Things I like about smoking
What are some of the things you like about your smoking?
• Smoking feels good

*
• I like watching the smoke and
the cigarette burn

a Smoking helps me relax and deal with
stress

• Smoking keeps away
withdrawals

• Smoking can be a good way to socialize
and bond with other smokers

• I like taking smoke breaks
throughout the day

a Smoking makes things more enjoyable

• Something else that is not on
this list

n Smoking helps me lose weight or
maintain my current weight

a None of these options

^repeat

^previous: • : -

^iiext

J|pause

< "^Mop

Figure 1. Example of pros and cons of tobacco use.

2) Feedback regarding the specific negative financial and health-related aspects unique to
their level of smoking (i.e., the amount of money per year they spend on cigarettes, the
percentage of adults who are non-smokers and how this percentage has increased over
time, how their negative effects from smoking compare to other smokers, and how much
higher their breath CO is than that of a non-smoker, see Figure 2).
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Figure 2. Example of personalized feedback regarding level of smoking.

3) Optional goal-setting regarding smoking, followed by a questions from the Change
Plan Worksheet (Miller & Rollnick, 1991, see Figure 3) to help the participant clarify
their goals and plan for obstacles (e.g., their specific reasons for quitting; the steps they
plan to take in quitting; and what could interfere with their change plan goal).

Using pre-planned algorithms, participants who were initially willing to set a quit
date proceeded directly to the third component. Those initially unwilling to set a quit date
engaged in the first and second component. For those participants who reached the end of
the second component and were still unwilling to set a quit date, the computer reflected
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Plan for Change
How will I know if my plan is working?
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How will you know If your plan to quit smoking Is working?
• If I can go a full day or week without
smoking

• If other people notice the changes
I am making

• If I have fewer cravings for cigarettes

• If I can walk into a corner store
and not buy cigarettes

o If I can cut the number of cigarettes I
smoke in at least half

• If I can refuse a cigarette that is
offered to me

a If I begin to feel like a non-smoker

• Something else not on this list

0 If my breathing and lung functioning
improves

D None of these options

BM repeat

^previous

;

pnexl

gjpaus©
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Figure 3. Example of optional goal setting regarding tobacco use.

their lack of readiness to change at this time and elicited information regarding
what signs would tell the participant that he/she did need to change.
Throughout this intervention, an animated and emotionally expressive cartoon
character acted as a narrator and guided the participant through the process. The narrator
read each item and also reflected back the participant's answers. This narrator, as well as
the touch-screen computer system, ensured that participants with minimal computer
literacy or poor reading skills could easily use and understand this computer program.
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A second CDMI session was administered at the end of the study period,
approximately four weeks after the initial intervention. This was done as an attempt to
boost motivation prior to follow-up and engage participants who may have not been
initially willing to set a quit date. It was also felt that a second intervention was needed
because within the context of brief interventions, more intervention time has been found
to be beneficial (Burke et al., 2003). As most relapses occur within a few weeks of
quitting, it was felt that a second CDMI within a relatively short time period may help to
increase or sustain the motivation of any participants who may have returned to baseline
levels of smoking.
The timing of this second intervention was chosen to be at the end of the study
period in part because of the nature of the pre-planned algorithms. It was felt that
engaging in the same (or very similar) intervention at a short time interval may not be of
much benefit or interest to participants. This second intervention also began by assessing
the participant's motivation for quitting and followed the same pre-planned algorithms as
the first session. The control group also underwent a second session with the computer on
a non-smoking-related task. At the completion of each of the two sessions, participants
were compensated with a $10 gift certificate.

Study period
Consistent with other investigations, the study period lasted a total of four weeks
(Robles et al., 2005; Shoptaw et al., 1996). During this time, all participants continued to
provide thrice weekly breath CO samples and complete the Tobacco Use and Beliefs
Measure and Brief Tobacco Quantity Assessment each time they provided a sample
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(Mondays, Wednesdays, and Fridays). Saliva cotinine was also randomly tested once a
week during this time. The only difference was in how the groups were compensated:
CDMI only and control group: These participants received $2 in gift certificates each
time they provided a breath CO sample and completed the brief questionnaires. This
compensation was provided regardless of the level of their breath CO. The fact that this
payment was non-contingent upon their smoking was stressed to these participants
through the study. Participants in these groups earned up to $30 in gift cards for
providing these samples, and $75 in gift cards overall.
CDMI plus CM group: This group primarily received compensation based on whether or
not they provided breath CO samples indicating a recent abstinence from cigarettes. In
order to receive this payment, their saliva cotinine also had to test below the cut-off on
the random days they were asked to provide this sample.
Participants in this condition earned $4 in gift cards for the first sample they
provided that indicated recent smoking abstinence. Consistent with Robles et al. (2005),
this amount increased by 50 cents for each consecutive day that they remained abstinent.
Participants could therefore earn $4.50 on Day 2, $5 on Day 3, and so on, up to a
maximum of $9.50 on Day 12. A sample that tested above the cut-off did not earn the
participant any compensation, and the amount they could earn the following day was
reset to $4. Budney et al. (2000) also used this incremental earning system in their study
of the combined effects of motivational enhancement and CM on marijuana use.
These participants also earned $1 in gift certificates for each time that they
provided a breath CO sample and completed the brief questionnaires. This payment was
provided even if the sample tested positive for recent tobacco use. This nominal payment

helped ensure that individuals who did not reduce their smoking still had some incentive
to continue to provide breath CO samples and information on the number of cigarettes
they had smoked.
The amount earned by participants in this group was therefore dependent on how
many negative samples they provided. For completing all parts of this study, participants
in this group earned $60. A participant that provided negative samples on each of the 12
days of the study would earn an additional $81. This potential payment amount falls
within the range of CM reinforcers reported in the literature. For example, reductions in
cocaine abuse amongst methadone maintenance clients have been reported with CM
payments as high as $3,369 (Dallery, Silverman, Chutuape, Bigelow, & Stitzer, 2001)
and as low as $25 per individual (Rowan-Szal, Bartholomew, Chatman, & Simpson,
2005).
Post-study
At the end of the five-week study period, all participants completed the following
questionnaires and were compensated with $5 in gift cards:
•

Fagerstrom Test for Nicotine Dependence

•

Smoking Self-Efficacy Questionnaire-12

•

Readiness to Change Questionnaire

•

Stages of Change Algorithm

•

Negative Effects of Smoking Questionnaire

•

Attributes of Treatment Questionnaire

•

Motivation for Change Questionnaire

•

Treatment Self-Regulation Questionnaire
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Follow-up
Follow-ups were conducted with all participants five weeks after study completion.
These follow-ups consisted of a breath CO sample, a saliva cotinine sample, and the
following questionnaires:
•

Fagerstrom Test for Nicotine Dependence

•

Smoking Self-Efficacy Questionnaire-12

•

Readiness to Change Questionnaire
Stages of Change Algorithm

•

Timeline Followback

•

Tobacco Use and Beliefs Measure.
Participants were compensated with $15 in gift cards for completing this follow-up.

Follow-up rates were 100% for the control group (N = 14); 100% for the MI only group
(N = 11); and 91.7% for the MI plus CM group (N = 11). At the end of the follow-up,
participants in the control group were offered the motivational intervention.

Measures
Primary Measures
Demographics Questionnaire. This questionnaire records information regarding age,
gender, highest level of education obtained, and questions related to socioeconomic status
(Appendix J). This questionnaire was computer-administered at baseline.

Smoking Background Questionnaire. This brief questionnaire assesses such variables as
age of first use of tobacco, number of years of use, and number of previous quit attempts
(Appendix K). This questionnaire was computer administered at baseline.

Breath carbon monoxide (CO). Breath CO readings were taken with the piCO-LO
Smokerlyzer Monitor® from Bedfont Scientific Ltd. Readings below 10 ppm place
individuals in the non-smoking range. According to the Bedfont website
(www.bedfont.com/downloads/Micro+.pdf), this product has a sensitivity of 1 ppm and
an accuracy of ± 2%. The breath CO readings were taken three times during the baseline
week, three times a week throughout the study period (12 samples total), and during the
follow-up assessment.

Saliva cotinine. Cotinine is the principal metabolite of nicotine. The NicAlert© Saliva
Nicotine Test was used to assess cotinine levels. This is a semi-quantitative and highly
sensitive test that detects levels ranging from 0 ng/ml to 1000+ ng/ml. Test readings
range from 0 (0-10 ng/ml) to 6 (1000+ ng/ml). A positive test is considered anything
above 10 ng/ml. Research has shown this test to have a specificity of 95% and a
sensitivity of 93% (Cooke, Bullen, Whittaker, McRobbie, Chen, & Walker, 2008). This
test requires participants to place a sample of oral fluid into a small collection container.
This fluid is then placed on a test strip, and results are visibly obtained within minutes.
This test was administered once during the baseline period, once a week throughout the
four-week study period (the day was chosen at random for each participant), and once at
follow-up. Participants were told that saliva samples were collected once per week but
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the day was not know to them ahead of time. Saliva cotinine was collected in addition to
breath CO, as the 17-hour half-life and a 48 hour window of detection of cotinine (Robles
et al., 2005) is much greater than that of breath CO. The cotinine test was only
administered once a week throughout the study, as the cost of these tests was prohibitive.

Timeline Followback (Sobell & Sobell, 1996). This measure was used to assess the
participant's tobacco use within the past 30 days (Appendix L). It was administered by
paper and pencil at baseline and follow-up. It was not necessary to administer this
measure at the end of the study period, as the Brief Tobacco Quantity Assessment (see
below) captured tobacco use during the 28-day study period. The Timeline Followback
makes use of a calendar with important dates and holidays noted. The participant is also
encouraged to record any personal markers, such as birthdays or significant life events.
Using these dates to enhance their recall, participants provide retrospective estimates for
their tobacco use over the specified time period.
The Timeline Followback method has been validated as a measure of tobacco use
(e.g., Shiffman, Paty, Kassel, Gnys, & Zettler-Segal, 1994) and is recommended for use
in evaluating specific changes in drug or alcohol use before and after treatment (Sobell &
Sobell, 1996). Several studies have shown the Timeline Followback to be quite reliable
over time, with the majority of test-retest correlations greater than .85 (Sobell & Sobell,
1996). It is considered the gold standard for self-report of tobacco use.

Brief Tobacco Quantity Assessment. This brief measure was administered by paper and
pencil three times a week throughout the baseline and study period. It asked the

participant to indicate how many cigarettes they have smoked since the last assessment
point (Appendix M). This allowed for a daily assessment of tobacco use throughout the
entire study period.

Tobacco Use and Beliefs Measure. This is a brief measure that has been modified from
the contemplation ladder (Biener & Abrams, 1991), a validated measure of smoking
cessation change. Using visual analogue scales (VAS), participants were asked to rate: 1)
their motivation to quit smoking, and 2) their confidence that they will be able to quit
(Appendix N). The VAS is a 10-centimeter line, on which the participant marks a point
between two anchors (i.e., 'not at all' and 'extremely'). The response is scored based on
how many millimeters from the left anchor the participant's mark is placed. This measure
was completed by paper and pencil three times a week throughout the baseline and study
period, and during the follow-up assessment.

Secondary Measures
Fagerstrom Test for Nicotine Dependence (Heatherton, Kozlowski, Frecker, &
Fagerstrom, 1991). This is a 6-item questionnaire that assesses one's level of dependence
on nicotine (Appendix O). Items include 'How soon after you wake up do you smoke
your first cigarette?' and 'Do you find it difficult to refrain from smoking in places where
it is forbidden?'. Scores can range from 0 (no to low dependence) to 10 (very high
dependence). This measure has been shown to have acceptable internal consistency
(Cronbach's alpha of .68; Etter, 2005) and has been found to be significantly correlated
with saliva cotinine levels (Pomerleau, Carton, Lutzke, Flessland, & Pomerleau, 1994).

35
This questionnaire was completed on the computer at baseline, study completion, and
during the follow-up assessment.

Smoking Self-Efficacy Questionnaire-12 (Etter, Bergman, Humair, & Perneger, 2000).
This 12-item scale assesses the confidence of smokers in their ability to abstain from
smoking in high-risk situations (Appendix P). This questionnaire includes both an
internal stimuli subscale (e.g., "When I feel depressed") and an external stimuli subscale
(e.g., "When I am with smokers"). Responses are given on a 5-point Likert scale ranging
from "Not at all sure" to "Absolutely sure". This measure has been shown to have
acceptable validity, high test-retest reliability (correlation coefficient of .95 for the
internal subscale and .94 for the external subscale; Etter et al., 2000), and high internal
consistency (Cronbach's alpha of .95 for the internal subscale and .94 for the external
subscale; Etter et al., 2000). This questionnaire was completed on the computer at
baseline, study completion, and during the follow-up assessment.

Readiness to Change Questionnaire (Rollnick, Heather, Gold, & Hall, 1992). This is a
12-item questionnaire designed to assess an individual's stage of change (Appendix Q).
The original questionnaire was designed to measure readiness to change problem
drinking, however for the purposes of this study the items have been modified to assess
tobacco use. There are three subscales: Precontemplation (e.g., "I don't think I smoke too
much); Contemplation (e.g., "Sometimes I think I should cut down on my smoking"); and
Action (e.g., "I have just recently cut down on my smoking"). Responses to each item are
given on a 5-point Likert scale ranging from -2 (strongly disagree) to +2 (strongly agree).
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An individual is said to be in the stage of change with the highest subscale score. This
measure has been found to have acceptable internal consistency (Cronbach's alpha of .73
for the precontemplation subscale, .80 for the contemplation subscale, and .85 for the
action subscale; Rollnick et al., 1992) and high test-retest reliability (correlation
coefficient of .82 for the precontemplation subscale, .86 for the contemplation subscale,
and .78 for the action subscale; Rollnick et al., 1992). This questionnaire was completed
on the computer at baseline, study completion, and during the follow-up assessment.

Stages of Change Algorithm (DiClemente et al., 1991). This single item measure ("Are
you seriously thinking of quitting smoking?") places individuals in different stages of
change based on their response (see Appendix R). There are four stages of change:
Precontemplation, Contemplation, Preparation, Action / Maintenance. This questionnaire
was administered at baseline, study completion, and at follow-up.

Negative Effects of Smoking Questionnaire. This is a 20-item questionnaire with items
from the Short Inventory of Problems (Miller, Tonigan, & Longabaugh, 1995) modified
to focus on cigarette smoking, as well as author-compiled items (Appendix S). This
questionnaire was administered to participants in the two motivational intervention
groups (CDMI only and CDMI plus CM) as part of the questionnaire package that they
completed at baseline, the end of the study period, and at follow-up. Control participants
only received this questionnaire at the end of the study period and at follow-up. It was
desired to use this as an outcome measure for all participants, although it was felt that
asking participants about the negative effects of their smoking may serve to increase their

motivation for change. To avoid having such a motivational effect on the control group,
these individuals did not complete the questionnaire at the beginning of the study period.

Attributes of Treatment Questionnaire. This author-compiled 12-item measure assesses
how participants feel about the treatment they received in this study (Appendix T).
Participants were reminded that this treatment includes any gift cards they received, the
time they spent with the computer, and any interactions they had with the researcher.
Items include "The treatment I received was respectful"; "The treatment I received was
unsupportive"; "The treatment I received made it worthwhile to change for a little bit"
and are answered on a 1 (Strongly disagree) to 5 (Strongly agree) Likert Scale. This
measure was computer-administered at study completion.

Motivation for Change Questionnaire. This author-compiled measure consists of five
items assessing internal motivation for change (e.g., "It was a goal I had set for myself)
and five items assessing external motivation for change (e.g., "I got paid for doing it")
(Appendix U). Responses are given on a 1 (Strongly disagree) to 5 (Strongly agree)
Likert Scale. This questionnaire was computer-administered at study completion.

Treatment Self-Regulation Questionnaire (Williams, Freedman, & Deci, 1998). This
15-item measure assesses motivation for change and includes items assessing
autonomous (e.g., "Because I felt I wanted to take responsibility for my own health"),
controlled (e.g., "Because it was easier to do what I am told than to think about it), and
amotivated (e.g., "I really didn't think about it") motivation (Appendix V). Responses are
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given on a 1 (Not at all true) to 5 (Very true) Likert Scale. This questionnaire was
administered at study completion.

Illicit drug use. Clinic clients provide frequent urine drug screens as part of their
methadone treatment. These drug screens indicate recent use of opiates and cocaine.
Participants in this study used other illicit substances too infrequently to be able to
statistically analyse any changes over time. The information from these drug screens was
valuable to the present study because some studies have found that when individuals quit
smoking, there tends to be reductions in overall substance use (e.g., Prochaska, Delucchi,
& Hall, 2004). This has also been found in a methadone-maintained sample of
individuals. Specifically, participants in a smoking cessation program provided more
opiate- and cocaine-free urines in the weeks that they meet criteria for smoking
abstinence (Shoptaw et al., 2002). It is thought that this occurs at least in part because
cigarette smoking is often a cue for alcohol or drug use.

Chapter 111
RESULTS
Data cleaning and evaluation
Missing data
As this was a longitudinal study and involved several time points, addressing
missing data was particularly important before data analysis could begin. The average
percent of days that participants failed to provide data (i.e., breath CO, self-reported
number of cigarettes smoked, and VAS ratings) throughout the study was 16% for
participants in the control group; 12% in the CDMI only group; and 19% in the CDMI
plus CM group. A one-way ANOVA found no significant difference between the groups
on this variable, F(2,34) = 1.16,/? = .33.
Intention to treat analysis is one method to analyze randomized controlled trials.
This method compares participants in the groups to which they were randomly assigned
regardless of their subsequent withdrawal or the treatment that they actually received
(Hollis & Campbell, 1999). This ensures that clinical effectiveness is not overestimated.
Although the application of this method varies widely in the literature, intention to treat
analysis is only possible when outcome data is available for all randomized participants
(Hollis & Campbell, 1999). Outcome data was not available for all participants who
enrolled in this study, and therefore sensitivity analysis was a more appropriate
procedure.
To address the issue of missing data, forward replacement was used for
participants who failed to provide data on no more than one day in a row and who missed
< 20% of the overall study days. Missing data for participants who missed more than two

days in a row or who had missing data for > 20% of the study days were averaged
between their day prior to and after the missing days. In order to assess the potential
impact of this missing data, we ran a sensitivity analysis on the main outcome measures
(breath CO, saliva, number of cigarettes smoked, and self-reported motivation to quit).
Participants for whom complete data was available were compared to participants for
whom data replacement techniques were used. No significant differences were found.
Differential follow-up rates were not analyzed, as only one participant of those
that completed the study was not available for follow-up assessment. As mentioned
previously, rates of study completion were not found to significantly differ between the
three groups.

Skewness
All variables were evaluated for skewness, and any showing over two standard
errors of skewness (Tabachnick & Fidell, 1996) were transformed. For this study (JV =
37), the critical value was .80. The analyses below are all based on variables that meet the
assumptions for ANOVA, although the details of each transformation are not reported.
For the main findings reported below, six of the variables required transformation,
with the most frequent being a square root transform.

Approach to data analysis
Current models of intervention development recommend a staged approach, part
of which includes an emphasis on appropriate pilot testing (exploring feasibility,
acceptability, and effect size estimation) prior to beginning fully powered Stage/Phase III
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clinical trials (Rounsaville et al., 2001). As noted above, this study was designed and
executed from within this conceptual framework. For this reason, in addition to the small
effects typically seen in smoking cessation studies (requiring very large sample sizes in
order to obtain significant effects; Lancaster & Stead, 2006a), null-hypothesis
significance testing was not the most appropriate means of evaluating these data. Rather
than relying solely on the criteria of statistical significance to guide our understanding of
the intervention effects, greater weight was given to patterns in the data and to measures
of effect size. This allowed for a more exploratory analysis of the findings and allowed us
to examine non-linear effects beyond the capacity of ANOVAs.
To conduct these exploratory analyses, ap value cut-off of < .30 was used. Any
group main effects or time x group interactions that had ap value under this level were
explored further with post-hoc tests and estimates of effect size.
Estimates of effect size were calculated using Cohen's d, d- (meam - mean2) /
(SDi" + SD2" / 2)"-', in cases where outcomes were continuous. According to Cohen
(1992), 0.2 is indicative of a small effect, 0.5 a medium effect, and 0.8 a large effect size.
In most cases, d was calculated using change scores (either post-study minus baseline or
follow-up minus baseline) in order to control for baseline values.
Change scores could not be calculated for repeated measures analyses. For these
analyses, partial eta-squared (n p ), a measure of effect size that is based on proportion of
variance accounted for rather than standard deviations, was obtained. This value was then
utilized to calculate Cohen's d, using the formula d - (2r 11- r 2 ) 05 . (Note: since partial
eta-squared is most accurate as a measure of effect size when the number of groups is two
[k = 2], separate repeated measures analyses comparing two groups at a time were run).

The main findings are presented here, although further results may be found in
Appendixes W-AC.

Tests of group equivalence
Demographics
The three groups were found to be equivalent on all key demographic variables.
As shown in Table 2, analyses of categorical variables through chi-square tests found no
difference between the groups on gender, x2 (2) = .50, p = .78; ethnicity, x2 (4) = .30,p .99; level of education, x2 (10) = 9.42,/? = .49; employment status, x2 (4) = 3.02,;? = .55;
or monthly income, X2 (8) = 6.03,/? = .64. It was also found that neither age, F(2,34) =
1.68,/? = .20, or number of days in treatment, F(2,33) = .44, p = .65, were significantly
different between the groups.

Baseline smoking measures
The three groups were equivalent on all key baseline smoking variables. No
significant difference between the groups was found on: age of first cigarette, F(2,33) =
1.22,/? = .31; age of first regular use of cigarettes, F(2,34) = .86,/? = .43; number of quit
attempts, F(2,32) = .58,/? = .57; number of total years smoked, F(2,34) = 2.60, p = .09;
longest time without a cigarette, F(2,33) = 2.06, p = .14; money spent each week on
cigarettes, F(2,34) = .40,/? = .67; or number of cigarettes per day, F(2,34) = .21,/? = .81
(Table 3).
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Table 2
Demographic statistics for each study group.
Control

CDMI only

CDMI plus CM

N (completers)

14

11

12

Mean age (SD)

46.0(11.1)

52.3 (9.1)

51.8(8.4)

Gender (%)
Male
Female

28.6
71.4

36.4
63.6

41.7
58.3

Ethnicity (%)
African American
Caucasian
Other

78.6
14.3
7.1

81.8
9.1
9.1

83.3
8.3
8.3

Education (%)
Less than Grade 10
Grade 10
Grade 11
Grade 12
GED
College/University

21.4
0
7.1
28.6
28.6
14.3

0
0
9.1
18.2
27.3
45.4

16.7
8.3
16.7
25.0
25.0
8.3

Employment status (%)
Unemployed
Employed part-time
Employed full-time

92.9
7.1
0

81.8
18.2
0

75.0
16.7
8.3

Monthly income (%)
Less than $500
$500-1000
$1001-1500
$1501-2000
$2001-2500
More than $2500

42.9
35.7
0
0
14.3
7.1

54.5
27.3
9.1
0
0
9.1

50.0
41.7
8.3
0
0
0

Mean days in treatment at
beginning of study (SD)

317.2(575.6)

201.7(300.8)

173.3 (226.8)
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Table 3
Baseline smoking statistcsfor each study group.
Control

CDMI only

CDMI plus CM

Mean (SD)

Mean (SD)

Mean (SD)

Age of first cigarette

18.2(7.4)

14.3 (3.0)

16.3 (6.5)

Age when started smoking regularly

20.3 (9.9)

16.7(3.6)

20.2 (6.6)

Number of total years smoked

24.1(11.8)

34.0(10.4)

32.1 (12.4)

Number of times tried to quit

5.6 (6.7)

5.1 (4.6)

7.9 (8.0)

Longest time without a cigarette (days)

136.0(221.1)
136.0
(221.1)

468.2 (672.2)

215.2(214.9)

Number of cigarettes each day

13.1 (5.9)

Variable

15.5(8.0)

15.5(8.2)

Amount spent each week on cigarettes ($) 31.5
31.5(20.4)
(20.4)

25.3 (10.6)

30.4 (20.4)

Have you ever talked to your counsellor
at this clinic about quitting smoking? (%)
No
Yes

81.8
18.2

91.7
8.3

71.4
28.6

Contingency payments
The average additional amount earned by participants in the CDMI plus CM
group was $16.35 (SD - $20.77, range = $0 to $56.50). The maximum that could be
earned was $81.
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Breath CO
The overall pattern of breath CO indicates a small increase in breath CO for the
control and CDMI only groups (each up approximately 10%) during the 5-week study
period, and a small to moderate decrease in breath CO for the CDMI plus CM group (a
decrease of approximately 25%; Figure 4).

Breath CO summary
The analyses are consistent in demonstrating the efficacy of the combination of
CDMI and CM in producing a during-treatment reduction in breath CO relative to control
and CDMI alone. To a lesser degree, there was also an effect for CDMI alone, relative to
control. This pattern of results reached the level of statistical significance for analyses of
breath CO reductions of 50% relative to baseline. The increased efficacy of the CDMI
plus CM group was only evident during treatment, and did not extend to the follow-up
period.

During treatment repeated measures
Statistical analysis of these values over the study period was done using a
repeated measures ANCOVA on breath CO readings for Week 1, Week 2, Week 3, and
Week 4(12 readings total). The covariate was average breath CO reading for the baseline
week. There was a non-significant trend towards a group main effect, F(2,32) = 2.46, p =
.10, r|2p = .13. No significant main effects were found for time, F(9,352) = 1.14,/? = .34,
n p = .03, and there was no time by group interaction, F(18, 352) = .92,p = .55, n p = .06.
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Figure 4. Average breath CO values across the study period and follow-up (fixed to zero
to account for baseline differences).

Given that the;? value for the group effect was well below the cut-off value of .30,
further exploration of these data was conducted. Partial eta squared values were
calculated for two group comparisons and were converted to Cohen's d. Across the study
period, the CDMI plus CM group showed a larger magnitude of reduction in breath CO
relative to CDMI alone (d= .82) and control (d= .97). There was a moderate effect size
difference between CDMI only and control (d= .52). This suggests that there was a clear
advantage for the combination of CDMI and CM in reducing breath CO over the length
of the study period.

Baseline versus post-treatment
Change scores were then calculated from baseline to Week 4. The difference in
these change scores between the groups approached significance, F(2,34) = 2.70, p = .08,
r|2p = .14. Because this;? value was well below the cut-off of .30, more statistical
exploration of this data was conducted.
Further analyses (Fisher's LSD post-hocs) revealed a significant difference
between the control and CDMI plus CM group (Mean Difference = 8.14,/? = .04) and a
non-significant trend towards a difference between the CDMI only and CDMI plus CM
group (Mean Difference = 6.89, p = .09). The CDMI plus CM group decreased their
breath CO while the other two groups increased from baseline to Week 4. No significant
difference was found between CDMI only and control (Mean Difference = 1.25, p = .74).
Change scores revealed a large effect size magnitude for the CDMI and CM
group over the CDMI only (d= .81) and the control group (d=l.\T).

The magnitude of

the difference on breath CO between the CDMI only and control group was almost zero
(d= .12). This also suggests that there was a clear advantage for the combination of
CDMI and CM on reducing breath CO levels at the end of the study relative to baseline.

Baseline versus follow-up
A statistical analysis of the breath CO follow-up data (controlling for baseline CO
levels) found no significant group differences, F(2,30) = .56,p = .58, n2p =.04. Because
this p value was above the cut-off of p<30, more statistical analyses were not conducted.
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Number of days breath CO was in non-smoking range
The total number of days breath CO was in the non-smoking range was compared
across the three groups (Figure 5). Statistical analysis using an ANCOVA (covarying on
baseline breath CO) showed a non-significant trend at thep < .30 level, F(2,32) = 1.71,/?
= .20, r|2p =.10. Two group comparisons were run and partial eta-squared was used to
calculate Cohen's d. In terms of magnitude of change, the CDMI plus CM group showed
more samples in the non-smoker range than the other two groups (d = .70 versus CDMI
only and d = .95 versus control), and the CDMI only group had more non-smoker
samples than the control group {d = .70).
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Figure 5. Total number of days across the study period that breath CO was in the nonsmoker range (error bars are standard deviation values).

Breath CO reductions relative to baseline
The number of days across the four weeks of the study that each participant had
reduced their breath CO reading by 50% relative to their average reading during the
baseline week was calculated (Figure 6). A univariate ANOVA was run on these data,
and a significant group difference was found, F(2,34) = 5.07,p = .01, if p =23. Further
analyses (Fisher's LSD post-hocs) indicated that the control group had significantly
fewer days of breath CO reduced by 50% relative to baseline than the CDMI only (Mean
Difference = .l2,p = .03) and the CDMI plus CM (Mean Difference = .16,/? < .01)
groups. There was no significant difference between the CDMI only and CDMI plus CM
groups (Mean Difference = .04, p = .47).
Estimates of effect size revealed that there was a large effect when the control
group was compared to the CDMI only (d = 1.10) and CDMI plus CM groups

(d=l.l7),

with the control group producing fewer samples that met this 50% reduction criterion.
When the CDMI only group was compared to the CDMI plus CM group, a moderate
effect was found (c/= .54), with the combined intervention group producing the largest
number of samples that showed a 50% reduction.

Measure of clinically significant breath CO reductions
A clinically significant reduction in breath CO was defined as a 25% decrease
relative to baseline. An ANOVA on follow-up breath CO values indicated no difference
between the groups on this value, F(2,30) = 1.38,/? - .27, although nine of the 35
participants provided follow-up samples below this cut-off.
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Figure 6. Number of days across the study period that breath CO was reduced 50%
relative to baseline (error bars are standard deviation values).

Saliva cotinine
The saliva cotinine readings across all participants decreased slightly between
baseline and Week 1 but then slowly increased, such that Week 4 readings were slightly
higher than baseline levels. When each of the three groups was examined separately, no
clear pattern of results emerged (Figure 7). The average saliva cotinine reading was in the
moderate range (modal score of 4 with a possible range = 0-6). At follow-up, all three
groups had slightly higher levels of saliva cotinine relative to baseline.
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Figure 7, Saliva cotinine values across the study period and follow-up (fixed to zero to
account for baseline differences)

Summary of saliva cotinine findings
There were no significant differences in saliva cotinine levels, either during
treatment or at follow-up.

Saliva cotinine across the study period
Statistical analysis of Week 1 to Week 4 values (using a repeated measures
ANCOVA with baseline saliva cotinine as the covariate) revealed no significant main
effects of time, F(3,99) = .82, p = .49, n2p =.02, or group, F(2,33) = .48,/? = .62, n2p =.03,
and no time by group interaction, F(6,99) = .49, p = .81, r| p =.03. Analysis of change
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scores also suggested no treatment effects on saliva cotinine readings at Week 4, F(2,34)
= .18, /? = .84,n 2 p = 01.

Saliva cotinine at follow-up
Similarly, no significant group differences were found on the change scores at
follow-up (controlling for baseline values), F(2,31) = .18,/? = .84, r\ p =.01.

Number of self-reported cigarettes
Across the study period
The pattern of results for all participants shows that from baseline to Week 1,
participants reduced their smoking from approximately 14 cigarettes per day to 10
cigarettes per day. Looking at the pattern of results for each of the three groups suggests
that the control and CDMI plus CM groups showed some degree of reduction each week
of the study. The CDMI only group showed reductions from baseline to Week 2, and then

increased the number of cigarettes smoked during Weeks 3 and 4 (although not back to
baseline levels).
The control and CDMI participants reduced their cigarette use by on average 20
cigarettes a week over the five weeks of the study, while CDMI plus CM participants
reduced their smoking by an average of just over 30 cigarettes a week during this time
(Figure 8).

53

105
100
95
90

Control
CDMI
-*^ CDMI plus CM

85
80
75
70
65
60
Baseline Week 1 Week 2 Week 3 Week 4

Figure 8. Number of self-reported cigarettes each week of the study period (total value)

Summary of findings for self-reported number of cigarettes
These results suggest that all three groups reduced their levels of self-reported
smoking over the study period to a similar degree, and that no clear advantage of one
intervention over the others was apparent. At follow-up, all three groups also maintained
this reduction relative to baseline levels. However, non-significant trends suggested that
the CDMI only group made additional post-treatment changes, whereas the CDMI plus
CM group increased use after the removal of treatment. This diverging trend led to an
apparent advantage for CDMI only in terms of change from post-treatment to follow-up.

During treatment repeated measures
Statistical analysis of the linear pattern of results was done using repeated
measures ANCOVA. The within subjects variables were the total number of cigarettes
smoked during each of the four weeks of the study and the covariate was total number of
cigarettes smoked during the baseline week. This analysis revealed no main effect of
time, F(7,864) = 1.65,;? = .13, r|2p = .05, or group, F(13,864) = .71,p = .75, n2p = .04,
and no time by group interaction, F(2,32) = 35, p = .71, n2p = .02.

Baseline versus post-treatment
Change scores were calculated for the number of cigarettes smoked during Week
4 minus the number of cigarettes smoked during the baseline week. These differences
were not significant across the three groups, F(2,34) = .31,/? = .74, n p = .02. Because the
p value was greater than .30, no further analyses were conducted.

Across pre-study, study period, and post-study
Participants overall showed a reduction in number of cigarettes smoked from
baseline to post-treatment (from 14 to 10 cigarettes/day, or approximately 6.5 fewer
packs of cigarettes a month). This reduction remained almost constant at follow-up
(Figure 9). Looking at the three groups separately revealed that the control group
followed this same pattern (i.e., sharply reduced the number of cigarettes they smoked
relative to pre-study and maintained this level at follow-up). The CDMI only group also
drastically reduced their use of cigarettes relative to pre-study and then continued this
reduction by approximately a pack per month at follow-up. In contrast, the CDMI plus
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Figure 9. Total number of cigarettes smoked pre-study (30 days), during the study period
(28 days), and post-study (30 days).

CM group reduced their use of cigarettes to a similar degree during the study period, but
then increased their use of cigarettes by approximately one per day at follow-up (still
down three cigarettes a day, or almost five packs per month, relative to pre-study).
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Pre-study versus study period
Analysis of the number of cigarettes smoked during the study period, minus prestudy levels of smoking showed similar levels of reduction across all three groups,
F(2,34) = .14,/? = .87,n 2 p = 01.

Pre-study versus post-study
Change scores were also calculated for the number of cigarettes smoked poststudy, minus pre-study. No difference between the groups was found, F(2,33) = .23, p .80,n 2 p = 01.

Study period versus post-study
Relative to number of cigarettes used over the study period, self-reported number
of cigarettes at post-study held steady for the control group, decreased for the CDMI only
group, and increased for the CDMI plus CM participants. A non-significant trend was
found at the;? < .30 level, F(2,33) = 1.30,/? = .28, n2 =.07, so effect sizes were calculated.
A small to moderate effect was found when the control group was compared to CDMI
only (d = .35), with the CDMI only group showing a continued decrease. A small to
moderate effect was also found when the control group was compared to CDMI plus CM
(d= .29), with the CDMI plus CM group showing an increase in number of cigarettes
smoked at follow-up. The increase in the use of cigarettes for the CDMI plus CM group
and the decrease for the CDMI only group resulted in a large effect when these two
groups were compared (d = .96).
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Relationship between biological and self-report measures
Correlations were run between the biological measures (i.e., breath CO and saliva
cotinine) and the self-reported number of cigarettes smoked. Regarding the relationship
between saliva cotinine and average breath CO reading, a significant correlation was
found for Week 3 (r = .41,/? = 01), Week 4 (r = 36,p = .03), and Follow-up (r=Al,p

=

.02). No significant relationship was found for Baseline through Week 2.
With respect to saliva cotinine levels and number of self-reported cigarettes
smoked, only a significant correlation was found for Week 1 (r = .36, p = .03). Number
of cigarettes smoked was, however, significantly correlated with breath CO at Baseline (r
= .46, p < .01), Week 1 (r = .43, p < .01), and Week 3 (r = .35, p = .03). No other
significant relationships were found.
These results suggest that the biological and self-report measures were reasonably
associated. Average breath CO readings appeared to best correlate with both saliva
cotinine levels and number of self-reported cigarettes smoked.

Motivation to quit - VAS ratings
Across all participants, the average motivation ratings were in the moderate range
(range = 61.3 - 66.5; possible range 0-100). CDMI only participants showed an increase
in motivation that peaked at Week 2 and was still elevated relative to baseline at followup (Figure 10). CDMI plus CM participants showed some decreases in motivation, which
were lowest at Week 3 but had returned to baseline levels at follow-up. Control
participants evidenced relatively constant levels of motivation, with an increase at followup.
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Figure 10. Average VAS motivation to quit smoking ratings for each week of the study
plus follow-up.

Summary of motivation rating findings
Effect sizes suggest that during the study period, CDMI only participants had
much higher levels of motivation than CDMI plus CM and control participants (who
evidenced the lowest levels of motivation). There were no significant differences between
the groups at follow-up.

During treatment repeated measures
Statistical analysis of these values (repeated measures ANCOVA with baseline
motivation as the covariate) found a non-significant trend towards a main effect of group,
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F(2,33) = 2.99,;? = .06, TI2P -.15. No main effect of time, F(5,363) = 1.09,/? = 37, r\\
=.03, or a time by group interaction, F(9, 363) = .75, p = .66, n2p =.04, were found.
Further analyses were conducted due to the group effect/? value being well under
the cut-off of < .30. These analyses (Fisher's LSD post-hoc) on the group main effect
found no significant differences: Control and CDMI only (Mean Difference = 12.83,/? =
.11); control and CDMI plus CM (Mean Difference = 3.98,p = .60); and CDMI plus CM
and CDMI only (Mean Difference = 8.84,/? = .28).
Two group comparisons were run and Cohen's d was calculated from partial etasquared. Very large effects were found when the CDMI only group was compared to the
control (d = -.90) and CDMI plus CM group (d = -1.35), with the CDMI only group
endorsing higher ratings than the other groups. A moderate effect was found between the
control and CDMI plus CM groups (d = .46), with the control group endorsing the lowest
ratings of motivation across the study period.

Baseline versus post-treatment
Change scores on average motivation ratings during Week 4 (minus baseline
ratings) were not significantly different between the groups, F(2,34) = .99,/? = .38, r|2p
= 39.

Baseline versus follow-up
Change scores were also calculated for the follow-up motivation ratings, minus
ratings at baseline. Statistical analysis revealed no significant group differences, F(2,32)
= .66,/?=.52,n 2 p = 04.

Confidence in ability to quit - VAS ratings
Across all participants, the overall confidence in ability to quit smoking ratings
were relatively flat across the entire study period. The average rating was in the moderate
range for each of the four weeks of the study plus baseline (range = 64.8 - 66.7; possible
range = 1-100) and did not show a large degree of variation. This suggests that the
average participant had a moderate degree of confidence that they could quit smoking
across the study period.
Separate analysis of the three different study groups revealed that the control
group showed relatively flat ratings across time while the CDMI only group showed a
sharp increase from baseline to Week 2 that leveled off in Weeks 3 and 4 (Figure 11).
The CDMI and CM group had similar ratings at baseline and Week 4, although their
lowest confidence ratings were in Week 3. At follow-up, the control and CDMI plus CM
groups had relatively unchanged confidence ratings compared to baseline. The
confidence ratings for the CDMI only group increased slightly from baseline to followup, but were down from post-study levels.

Summary of confidence in ability to quit smoking findings
There was a significant group difference in confidence ratings across the study
period, with CDMI endorsing the highest levels of confidence and the control group
endorsing the lowest. Effect size estimates revealed a similar pattern of results when poststudy ratings were compared, relative to baseline. No group differences were found at
follow-up.
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Figure 11. Average VAS confidence in ability to quit smoking ratings for each week of
the study plus follow-up.

During treatment repeated measures
Linear analysis of these patterns (using a repeated measures ANCOVA with
baseline confidence as the covariate) revealed a significant main effect of group, F(2,32)
= 3.59, p =.04, r|2p =.18. No main effect of time, F(8, 352) = .63,;? =.74, n2p =.02, or time
by group interaction, F(\6, 352) = 1.21,p =.26, TJ P =.07, were found.
Post-hoc analyses (Fisher's LSD) on the group main effect found no significant
differences: Control and CDMI only (Mean Difference = 1617.56,;? = .12); Control and
CDMI plus CM (Mean Difference = 361.60, p = .72); and CDMI plus CM and CDMI
only (Mean Difference = 1255.96,;? = .25).
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Two group comparisons were run and partial eta-squared values were used to
calculate Cohen's d. Very large effects were found when the CDMI only group was
compared to the control (d= 1.01) and CDMI plus CM groups (d= 1.30), with the CDMI
only group endorsing higher levels of confidence across the study period. Only a small to
moderate effect was found when the control and CDMI plus CM group was compared (d
- .35), with the control group showing slightly lower confidence ratings.

Baseline versus Post-treatment
To further examine any group differences over the study period, change scores
were calculated for Week 4 values minus baseline confidence ratings. A non-significiant
trend (at the p < .30 level) was found, F(2,34) = 1.92,/? - .16, n2p =.10. Effect size
calculations revealed that the control and CDMI plus CM groups had similar small
decreases in confidence across the study period (d = .10). The increase in confidence
shown by the CDMI only group produced a large effect relative to the control (d = .74)
and CDMI plus CM conditions (d = .80).

Baseline versus follow-up
Change scores were also calculated from baseline to follow-up for the confidence
ratings. A univariate ANOVA was run and no significant difference between the groups
was found, F(2,32) - .57,p = .57, n2p =.03.
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Negative Effects of Smoking Questionnaire
The overall ratings on the Negative Effects of Smoking Questionnaire remained
relatively steady over time and did not show much variation (range = 25.6 - 27.6;
possible range = 0-60). These values indicate that the average participant endorsed a
moderate degree of negative effects from their smoking (Figure 12). When each group
was examined separately, a divergent pattern of results emerged. At baseline, CDMI only
participants endorsed more negative effects of their smoking than the CDMI plus CM
group (this measure was not administered to control participants at baseline). At poststudy and follow-up, the CDMI only group slightly increased the number of negative
effects that they endorsed, while the CDMI plus CM group endorsed fewer negative
effects relative to CDMI only and relative to their own baseline. The control group scores
fell between the other two groups at post-study and follow-up.
Cronbach's alpha was run to test for internal consistency of this measure. Alpha
levels were .92 at baseline, .90 at post-test, and .90 at follow-up.

Summary of negative effects of smoking results
Significant differences were found between the CDMI only and CDMI plus CM
groups, with the CDMI only participants endorsing significantly more negative effects of
smoking at post-study and follow-up, relative to baseline.

Baseline versus post-study
Change scores were calculated for the difference between baseline and post-study.
This could not be calculated for the control group, as they did not complete this measure
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Figure 12. Total scores on the Negative Effects of Smoking Questionnaire at baseline,
post-study, and follow-up

at baseline. A univariate ANOVA revealed a significant group difference, F(l,21) = 4.76,
p = .04, n 2 p =. 19. Effect size calculations revealed that this was a large effect for the
comparison between CDMI plus CM and CDMI only (d = -.93), with the CDMI only
group showing an increase in their total score over time. The number of negative effects
endorsed by the CDMI only group increased over the study period, while they decreased
for the CDMI plus CM group.
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Baseline versus follow-up
Change scores from baseline to follow-up were also calculated for the CDMI only
and CDMI plus CM groups. These change scores were found to be significantly different
between the two groups, F(\,2\) = 5.91,p = .02, r\2p =22. Effect size calculations
indicated that the magnitude of the difference between the groups was large (d= 1.03),
with the CDMI only group endorsing more negative effects.

Motivation for Change Questionnaire
Internal Motivation Subscale
The Motivation for Change Questionnaire was administered only at post-study.
Analysis of the internal motivation subscale showed that the groups were virtually the
same on their average score and all showed a relatively high degree of internal motivation
(M= 18.6; possible range 0-25). This similarity was confirmed with a univariate
ANOVA, F(2,34) = .03,p = .98, n2p = .00 (Table 4). Cronbach's alpha indicated that the
internal subscale had an acceptable level of internal consistency, with an alpha level of
.79.

Summary of results for the motivation for change subscale
Effect size estimates suggest that the CDMI plus CM group endorsed the highest
levels of external motivation, while the CDMI only group endorsed the lowest levels. No
difference was found between the three groups on the internal motivation subscale.
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Table 4
Motivation for Change Questionnaire subscale scores.
Control

CDMI only

CDMI plus CM

Mean (SD)

Mean (SD)

Mean (SD)

Internal subscale

18.7(5.1)

18.8(4.4)

18.4(3.6)

External subscale

11.6(3.9)

11.0(2.0)

13.2(2.9)

External Motivation Subscale
The external motivation subscale scores were considerably lower across all
groups than the internal motivation scores. Across all participants, a moderate degree of
external motivation was endorsed (M = 11.9; possible range 0-25). The CDMI only group
endorsed the lowest degree of external motivation while the CDMI plus CM group
endorsed the highest.
A test of internal consistency indicated that the external subscale had a low
Cronbach's alpha value of .41.
Statistical analysis revealed a non-significant trend (at the/? <.30 level) between
the groups, F(2,34) = 1.66,/? = .21, n p = .09. Exploratory effect size calculations showed
a small to moderate effect size between the control and CDMI only group (d = -.42), with
the CDMI group scoring lower on external motivation than the control. There was a
moderate to large effect size for the comparison between the control and CDMI plus CM
group {d - .72), with the CDMI plus CM group endorsing more external motivation. This
magnitude of effect was largest for the CDMI only and CDMI plus CM group (d= 1.01).
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Treatment Self-Regulation Questionnaire
Summary of treatment self-regulation questionnaire findings
Effect sizes estimates suggest that the CDMI plus CM group endorsed the highest
level of amotivation, while the CDMI only group endorsed the lowest level. No group
differences were found on the autonomous or controlled subscales.

Autonomous Subscale
Overall, the participants had relatively high ratings on the autonomous subscale
(M= 5.8; possible range 1-7), indicating that they felt a large degree of autonomy. No
significant differences were found between the groups, F(2,33) = .08,/? = .92, r\ p = .01
(Table 5). Cronbach's alpha was .81 for this subscale, indicating an acceptable level of
internal consistency.

Table 5
Treatment Self-Regulation Questionnaire subscale scores
Control

CDMI only

CDMI plus CM

Mean (SD)

Mean (SD)

Mean (SD)

Autonomous subscale

5.7(1.3)

5.9(1.2)

5.9(1.1)

Controlled subscale

2.8(1.4)

3.0(1.7)

3.4(1.2)

Amotivated subscale

2.5(1.0)

2.2(1.1)

3.3(1.4)

68
Controlled Subscale
Across all participants, ratings on the controlled subscale were in the moderate
range (M= 3.1; possible range = 1-7) at post-study, indicating that participants felt a
moderate degree of control was being exerted over them. No significant difference
between the groups was found on this subscale, F(2,33) = .56, p - .57, r| p = .03. There
was found to be a large degree of internal consistency for this subscale (Cronbach's alpha
of .82).

Amotivated Subscale
At post-study, the average amotivated subscale score across all participants was
found to be in the low to moderate range (M- 2.7; possible range = 1-7), indicating that
the average participant felt a moderate degree of amotivation (i.e., a lack of motivation).
Cronbach's alpha was found to be quite low for this subscale (.20). A univariate ANOVA
found a non-significant trend towards a difference between the groups on this subscale,
F(2,33) = 2.74, p = .08, n2p = .14. Because this trend was well under the p < .30 cut-off,
post-hoc analyses were done. These analyses (Fisher's LSD post-hoc) revealed a
significant difference on this variable between the CDMI only and CDMI plus CM group,
with the CDMI plus CM group endorsing more amotivation than the CDMI only group
(Mean Difference = 1.12,/? = .03). Control group amotivation ratings fell between the
other two groups but were not significantly different from either.
Effect size estimates showed large effects when the CDMI plus CM group scores
were compared to the control (d = -.84) and CDMI only groups (d = -1.00), with the
CDMI plus CM group having the highest amotivation score. A moderate effect was found
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when the control and CDMI only groups were compared (d= .58), with the control group
having the higher amotivation score.

Attributes of Treatment Questionnaire
As shown in Table 6, the overall rating of satisfaction with the various
interventions across all three study groups was relatively high (M= 3.94, SD = .39;
possible range 1-5). A test of internal consistency revealed a Cronbach's alpha value of
.65. An analysis between the groups revealed no significant difference, F(2,34) = .36,p =
.70, n2p = .02.

Table 6
Attributes of Treatment Questionnaire scores at post-study

Attributes of Treatment
Total Score

Control

CDMI only

CDMI plus CM

Mean (SD)

Mean (SD)

Mean (SD)

3.88 (.47)

4.01 (.42)

3.93 (.26)

Chapter IV
DISCUSSION
Overview of main findings
This exploratory/developmental study was intended to allow examination of
patterns of effects, in order to inform subsequent and more fully powered trials. In such
research, the hope is that effects of at least moderate magnitude will be obtained, with
statistical significance being a less crucial—but still desirable—secondary goal. Many
interesting effects of moderate magnitude and greater were observed, some of which
reached statistical significance. This study was therefore highly successful in reaching the
above goal.
Overall results suggest that both CDMI only and CDMI plus CM may lead to
positive effects with respect to smoking and smoking-related variables. However, there
were clear differences in the kinds of outcomes for which each intervention appeared
best. Participants in the CDMI plus CM group showed the greatest reductions in breath
CO over the course of the study period. These reductions reached statistical significance
for some analyses. In contrast, the CDMI only intervention was associated with better
outcomes in terms of several motivation-related variables. Therefore, it appears that the
combination of an intervention aimed at increasing internal motivation (CDMI) with an
intervention that involves a high degree of external motivation (CM) interferes with the
internalization of motivation yet exerts a powerful influence on behaviour change, at least
in the short term.
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Changes in smoking behaviour
With respect to the changes in smoking behaviour, results are mixed. As
mentioned above, the breath CO readings for the CDMI plus CM participants were the
lowest of the three groups across the study period. That is, the combination of CDMI and
CM was most efficacious in producing reductions in smoking behaviour, as measured by
breath CO. CDMI alone was more efficacious than control. The analysis of this data
closely approached statistical significance and reached the level of significance in one
instance. These differential effects were only present while the interventions were in
place, as no differences were found at five-week follow-up.
These breath CO findings are inconsistent with the number of cigarettes
participants reported smoking, although these two measures were found to be
significantly correlated at half of the time points. All three study groups reported
equivalent reductions in number of cigarettes smoked during the study period. The fact
that even control participants greatly reduced their level of smoking is consistent with
other studies of substance abuse interventions, in which participation in baseline
assessment is often associated with substantial reductions in use (e.g., Epstein, Drapkin,
Yusko, Cook, McCrady, & Jensen, 2005).
The findings at follow-up with respect to number of cigarettes smoked suggest
some differential intervention effects. While all three groups maintained their reductions
relative to baseline, there was some evidence to suggest that the CDMI only group
continued to reduce their levels of smoking relative to the study period. In contrast, the
CDMI plus CM group had increased their levels of self-reported cigarette use relative to
the study period. This finding is consistent with study hypotheses and previous studies of

CM, which typically find increases in target behaviour when the contingencies are
removed (e.g., Hey & Perera, 2006b; Prendergast et al., 2006).
The above findings for breath CO and number of cigarettes smoked are also
inconsistent with levels of saliva cotinine. Saliva cotinine was found to be moderately
associated with breath CO levels, but poorly related to number of cigarettes smoked. This
measure found no difference in cotinine levels across time or between the three study
groups. As these cotinine tests have been found to have an excellent level of specificity
and sensitivity (Cooke et al., 2008), it must remain a possibility that there were no
smoking-related reductions produced by either of the two interventions, relative to
control.
The difference in findings between the two biological measures (breath CO and
saliva cotinine) merits attention. The primary difference between these measures is that
breath CO is under more participant control than saliva cotinine. That is, level of saliva
cotinine remains more constant in the body than breath CO, which will begin to decrease
soon after a cigarette has been smoked. It is therefore possible that participants learned to
alter their smoking habits so that their breath CO was reduced at the time of testing (i.e.,
refraining from smoking prior to providing a breath CO sample). This explanation is
consistent with the finding that although breath CO was lowest for the CDMI plus CM
group, the number of cigarettes smoked across the study period was reduced to a similar
degree by each of the groups. Saliva cotinine readings (which would be less affected by
minor alterations in one's pattern of smoking) did not show differential changes over the
study period. It is therefore possible that CDMI plus CM participants learned to modify
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their smoking in an attempt to obtain contingency payments by providing samples below
the set cut-offs.
This hypothesis is consistent with anecdotal reports from a CDMI plus CM
participant who frequently earned CM payments by providing a breath sample in the nonsmoker range. This individual reported to the investigator on several occasions that her
reduced breath CO samples were due to the fact that she had reduced her overall smoking
levels but had also changed her smoking pattern, such that she did not smoke for the 12
hours prior to testing.
If this explanation is true, it suggests that the reductions in breath CO shown by
the CDMI plus CM participants may not reflect true reductions in smoking. The effects
seen in the control and CDMI only group should not be affected by this hypothesis, as
their level of breath CO had no impact on payments that they received for simply
providing a sample. Some CM studies require participants to provide breath CO samples
more than once a day, and a more frequent sampling schedule may help address this issue
in future research.
The possibility must also be acknowledged that relationship with the researcher,
even in the context of a formalized research protocol, may have contributed to the
changes observed in the CDMI and CM group. That is, an interpersonal aspect of
reinforcement (e.g., acknowledgement by another of smoking-related changes) outside of
the CM payments may have accounted for some degree of change in this condition.
While being mindful of the above possible explanations for the results, these
findings suggest that CDMI plus CM was most effective in reducing smoking during the
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study period (as measured by breath CO), while CDMI only was most effective at
reducing smoking at five-week follow-up (as measured by number of cigarettes smoked).

Changes in motivation
Across the study period, participants who received only the CDMI were found to
be highest on visual analogue scale measures of motivation to quit smoking. There were
no differential effects between the groups on motivation to change at follow-up. This was
partly consistent with hypotheses, which predicted a better motivation outcome for CDMI
participants at post-study and follow-up. CDMI only participants were also found to
endorse the most negative effects related to their smoking. Developing an awareness of
positive and negative aspects of behaviour change is a key component of MI and may
also be taken as a possible indicator of growing motivation to change smoking behaviour.
There is further indication that the combination of CDMI plus CM impacted
motivation relative to CDMI alone. Specifically, the CDMI plus CM group endorsed the
highest levels of external motivation and amotivation (i.e., lack of motivation) relative to
the other two groups.
Therefore, while CDMI only participants endorsed the most motivation to change,
participants who also received the CM appeared to be externally motivated. Although the
effects of CDMI and CM cannot be teased apart, it can be hypothesized that the CM
overshadowed the CDMI for these participants and interfered with the internalization of
motivation to change. However, it is also worth noting that motivation to change is a
highly reactive variable that is responsive to changes in the target behaviour (in this case,
smoking). For example, someone who has successfully quit may endorse less motivation
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or need to change, because he or she has already done so. It is therefore possible that the
CDMI plus CM condition appears less motivated to quit smoking simply because they
had actually reduced their levels of smoking to the largest degree. This suggestion is
supported by the increase in motivation seen in this group from post-treatment to followup, during which time their level of smoking appears to have increased.
It is also important to note that while there was a difference between the groups
on level of external motivation, there was no difference on level of internal motivation
(as measured by the Motivation for Change Questionnaire). This is inconsistent with
hypotheses based on the SDT and is in contrast to the visual analogue scale (VAS)
ratings of motivation, on which the CDMI only participants rated themselves as most
motivated. This VAS was less specific about the source of motivation (i.e., "How
motivated are you to quit smoking"). While it can be assumed that this is capturing
internal motivation, these results should be interpreted with some caution.

Implications of findings and potential limitations
These findings suggest that low-intensity CM may have positive effects on
cigarette smoking (as measured by breath CO) while the contingencies are in place. This
has important implications for more widespread use of such an intervention, as the cost of
such programs is often a barrier to implementation. In this study participants in the CM
group were offered the opportunity to earn $81 to stop smoking (the average actually
earned by participants was $16). Even at this low level of potential payment, a significant
reduction in breath CO was found over the study period.
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While the combination of CDMI and CM produced reduced breath CO over the
study period, CDMI alone was the most effective intervention at reducing number of
cigarettes smoked at five-week follow-up. This condition also produced the highest level
of motivation for change. The combination of CDMI and CM produced reductions in
breath CO but was more costly to run and did not show reductions in number of
cigarettes smoked at follow-up relative to the control condition. Due to the more lasting
effects and low cost to implement, the CDMI on its own offers clear advantages to the
combined approach of both CDMI and CM.
These findings also suggest that if harm reduction is a desired outcome of
treatment, simple monitoring of cigarette use may be enough to affect some degree of
change. Although control participants did not show the same degree of breath CO
reductions and motivation to change evidenced by the intervention groups, it appears that
frequent monitoring of cigarette use or other study-related factors in the absence of direct
intervention led to decreases in self-reported number of cigarettes smoked. These
decreases in cigarette use were comparable to those reported by the intervention groups
and represent a decrease of approximately three cigarettes per day relative to pre-study.
In fact, these overall reductions across all participants were larger than the between-group
differences. Furthermore, these reductions were maintained in the control group even at
five-week follow-up.
Previous studies would suggest that it is not only the frequency of assessment that
leads to changes in the control condition, but any assessment at all. It has been found that
even brief baseline assessment is often enough to lead to changes in behaviour. Among
the hypothesized reasons for these pre-treatment changes are the provision of
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information, natural change as the result of self-observation, and elicitation of personal
concerns and reasons for change (Epstein et al., 2005).
In a study of women seeking treatment for alcohol abuse or dependence, Epstein
et al. (2005) found that significant reductions in drinking occurred during each stage of
the pretreatment assessment. As a result, 44% of participants reported becoming abstinent
prior to entering treatment. Kypri, Langley, Saunders, and Cashell-Smith (2007) have
also demonstrated an assessment effect with lasting impact. Relative to an informationonly group, individuals given information and a ten minute assessment of their alcohol
use reported significantly lower consumption and alcohol-related problems at 12-month
follow-up.
The impact of this pre-treatment change is that it decreases the chances of finding
differential treatment outcomes and must be acknowledged as a potential limitation in the
present study. It is possible that limiting the length and frequency of assessment in the
control condition may have led to larger effects.

How does this build on previous research?
The findings from this study are somewhat consistent with previous studies.
Specifically, Budney et al. (2000) found that a group that received motivational
intervention, behavioural skills coping, and CM had greatest reductions in marijuana use
across the study period. This is consistent with our findings that the combination of
motivational intervention and CM produced the greatest reductions in smoking (as
measured by breath CO) while the interventions were in place. Kadden et al. (2007) also
found that the two groups that received CM had the best outcomes during the study

period. However, the combination of motivational enhancement, cognitive behaviour
therapy, and CM produced the greatest degree of marijuana abstinence at follow-up. This
suggests that either the cognitive behavioural therapy or motivational enhancement may
have had a delayed effect that was not realized until the follow-up period. The results of
this study, coupled with SDT, would suggest that the motivational enhancement
component may have produced these reductions in marijuana use at follow-up. This is in
contrast with a study that targeted cocaine use in methadone maintained individuals
(Epstein, Hawkins, Covi, Umbricht, & Preston, 2003). While CM alone produced initial
reductions in cocaine use while the contingencies were in place, at 12-month follow-up it
was the combination of CM and cognitive behaviour therapy that produced the greatest
reductions. Epstein et al. (2003) hypothesized that the late gains in the CM and cognitive
behaviour therapy group were the result of a gradual process of learning that took place
with the cognitive behavioural component. The exact mechanisms of this delayed effect
remain unknown, but it is evident that motivational intervention may result in a similar
"sleeper" effect.
With respect to our finding that the combination of motivational intervention and
CM may have interfered with the internalization of motivation to change, motivation was
not assessed by Kadden et al. (2007). Budney et al. (2000) found that self-reported
motivation decreased for all three groups across the study period, and was in fact lowest
for the group receiving motivational enhancement.
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How do the results fit with the self-determination theory?
The results of this research appear to support the SDT and suggest that the two
interventions (CDMI and CM) fall on opposite poles of the continuum of autonomy. That
is, the combination of CDMI and CM (which led to high levels of external motivation)
effectively reduced breath CO while the intervention was in place but increases in
number of cigarettes smoked were evident at follow-up. This is consistent with behaviour
towards the amotivated end of the continuum. This was confirmed by the higher ratings
of amotivation evidenced in the CDMI plus CM group.
In contrast, the CDMI alone produced more lasting changes. This is more
consistent with behaviour at the intrinsic regulation end of the spectrum. Furthermore, the
results obtained from the combined intervention group (CDMI plus CM) are consistent
with the results of Deci (1971) who found that external rewards interfere with the
internalization of motivation. This is evident in the way in which CDMI plus CM
participants differentiated themselves from CDMI only participants by showing
continued reductions in cigarette use only when the intervention was in place.
Research related to the SDT has found that amotivation is associated with poor
treatment outcomes (Senecal, Nouwen, & White, 2000). This is somewhat consistent
with the results of this study, in which the CDMI plus CM group endorsed significantly
higher levels of amotivation than either CDMI or control. It is possible that participants
in this condition acknowledged the shorter term benefits of this treatment (i.e., contingent
reinforcement), but did not view it as a method of supporting longer term goals (e.g.,
quitting smoking).
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The results are also consistent with SDT, in that this theory would suggest that
behaviour change might occur at different times for the CDMI plus CM and CDMI only
groups. That is, according to SDT, CDMI plus CM participants should evidence more
immediate changes in behaviour, while behaviour change may occur over a more
extended period of time in the CDMI only group, as motivation for change builds. This
appears to be the pattern in the present study, in that changes for the CDMI group were
slower to appear, but also extended past the intervention period. It may be that longer
follow-ups would capture continued decreases in smoking behaviour for this CDMI only
group.

What does this tell us about computerized approaches to motivational intervention?
One goal of this research was to assess the efficacy of a brief computerized
motivational intervention in affecting smoking-related behaviour change. Affecting
change in smoking behaviour is traditionally quite difficult regardless of the intervention
used (Lancaster & Stead, 2006a). With respect to traditional motivational interventions,
meta-analyses suggest that the effect size for such interventions relative to no
treatment/placebo ranges from .11 (Burke et al., 2003; Burke et al., 2004) to .14 (Hettema
et al., 2005). Over this five-week study, the key measures found intervention effects for
control relative to CDMI of .23 for saliva cotinine, .44 for number of cigarettes smoked,
.52 for breath CO, and .90 for motivation to quit. In all cases, CDMI demonstrated more
favorable outcomes than control. These results suggest that this computerized
intervention (in which changes in smoking behaviour, rather than complete abstinence
was assessed) was more efficacious at producing behaviour change over the course of the
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study than previous research examining traditional MI for smoking cessation. These
effects are on par with the general effects associated with motivation interviewing
relative to control across all areas of behaviour change (i.e., .36 to .56; Burke et al.,
2004).
While the CDMI was efficacious at producing changes in smoking behaviour and
motivation, acceptability must also be considered. Although the ratings of response to
treatment received were not significantly higher than the other two groups, participants
who received the CDMI rated the intervention in positive ways such as helpful,
understanding, supportive, enjoyable, respectful, and as something that made them want
to change. They also endorsed the intervention as something they would recommend to
others. These positive ratings are consistent with previous studies of similar computerized
interventions (Ondersma et al., 2005; Ondersma et al., 2007) that found participants gave
high ratings of approval to the intervention.
These results suggest that computerized interventions are well accepted by
consumers and may produce smoking-related behaviour change that is more stable in the
longer-term, than more expensive and time-consuming traditionally delivered
motivational interventions.

Directions for future research
The results of this small sample, exploratory study suggest many different areas
for future exploration. Based on the promising and intriguing results of this research, it is
clear that larger scale studies of this kind are needed. Specific suggestions are discussed
below. First, initial studies further exploring the combined efficacy of CM and CDMI
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may wish to use larger contingency payments in order to more clearly differentiate
treatment effects. While the relatively small payments used in this study (maximum
payment of $81) were effective at producing changes in smoking behaviour, research has
shown that lower magnitude incentives produce smaller degrees of change than higher
magnitude incentives (but more than no incentives at all); (Silverman, Chutuape,
Bigelow, & Stitzer, 1999). In order to maximize any differential treatment effects and
increase the odds of statistical significance, larger contingency payments may be welladvised. Longer-term research, however, may wish to focus on smaller contingencies, as
any level of monetary payment is a significant barrier to implementation in most
community or hospital settings. Recent research has pursued such contingencies as the
opportunity to win prizes (e.g., Alessi, Hanson, Wieners, & Petry, 2007; Olmstead,
Sindelar, & Petry, 2007). This option has shown itself to be both cost-effective and
efficacious at producing behaviour change.
An even more intriguing option regarding contingency payments is to examine if
there are contingencies that are efficacious at reducing smoking behaviour but will not
interfere with the internalization of motivation. Non-monetary rewards such as paid job
training (Silverman, Svikis, Robles, Stitzer, & Bigelow, 2001) and access to subsidized
housing (Schumacher et al., 1999) have previously been used as effective contingencies
in reducing substance abuse. There may also be methods of framing external incentives
(e.g., as a participant-chosen means of supporting their own change goals). These
possibilities suggest that not all CM may be associated with amotivation, as was found in
the present study. By giving individuals a choice of contingencies and input on whether
this is the best method to help them reach their goals, it may be possible to foster
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autonomy with this approach. The impact of varying types of rewards on motivation
should also be more fully explored, as it may be that different types of contingencies are
complementary to motivational interventions.
Future researchers may also wish to manipulate the timing of the CDMI and CM
in relation to each other. For example, it may be beneficial to expose participants in the
combined condition to each intervention but not allow the interventions to overlap. In
particular, it may be worth examining whether a CM period followed by a CDMI
intervention upon termination may be more effective than applying both interventions at
once. These results suggest that the CM will produce reductions in smoking behaviour
that may lead to an experience of competence. This sense of competence is felt to be a
key condition to enhance autonomous motivation (Deci & Ryan, 1985). Therefore, it may
be possible that the later introduction of the CDMI may present an opportunity to build
on smoking reductions produced by the CM. This may lead to a greater ability to
internalize motivation, and therefore more lasting treatment outcomes. Similarly, it may
also be desirable to wean participants off of CM by reducing the incentives over time.
This may also allow for participants to build on their smoking reductions from the CM
and internalize their motivation to change as the CM incentives are decreased. An
additional point to consider is the apparent plateau in motivation level that the CDMI
only group evidenced beginning at Week 2. Future research should explore whether a
smaller interval of time between CDMI sessions (approximately four weeks in the current
study) would be more optimal in fostering continued motivation.
Additional methodological changes worth pursuing include the inclusion of a CM
only group. While not feasible in the present study because of budget constraints and a

84

small sample size, a four group design (i.e., control, CDMI only, CM only, CDMI plus
CM) might help to more clearly understand the combined intervention group. It was
impossible to tease apart the differential effects of the two interventions in the CDMI and
CM group, and a CM only condition might serve as a useful comparison to help further
determine any potential benefits of the combined intervention.
Another methodological consideration involves incorporating more follow-up
time points. There is some indication from these findings that the effects of the CDMI
may be appear more slowly, as there were apparently continued positive effects on
number of cigarettes smoked between post-study and five-week follow-up for the CDMI
only group. It would be helpful to obtain more information about this. Additionally, at
five-week follow-up all three study groups self-reported smoking significantly fewer
cigarettes than at baseline. More longer-term follow-up would help determine if and
when smoking returns to baseline levels.
The results of this small sample exploratory study are useful in providing
preliminary ways of thinking about the effects of an intervention combining both internal
and external motives for smoking-related behaviour change. It is likely that these
mechanisms of change interact in highly complex ways, and further research is needed to
build on and expand these findings.
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APPENDIX C
Screening Questionnaire
You are being asked to answer some brief smoking-related questions. These questions
should take less than five minutes of your time. If you choose to complete this brief
questionnaire, you will earn a $1 McDonald's gift certificate.

By answering these questions, you may also qualify for a study that will look at
smoking-related behaviour in methadone-maintained individuals.

If you qualify for this later study, you may earn up to $70 in gift cards over the period of
several weeks.

If you choose to complete these questions, your questionnaire will only be identified by
a unique study number. Your name will not appear anywhere.
You are free to choose whether or not you want to complete this brief questionnaire.
You may also complete the questions and later decide that you do not want to
participate in the study.

If you do qualify for the study, a researcher will contact you in the next few weeks.
Please take your time to read the questions carefully and answer them as truthfully as
you can. If you have any questions, please ask the researcher for assistance.
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1. Gender:

Male

Female

2. Age:

3. Ethnicity: African American

Caucasian

Other

4. Please circle ALL the days that you currently dose at the clinic:
MON

TUES

WED

THURS

FRI

5. Are you currently taking the medications BUPROPION. WELLBUTRIN or
ZYBAN ?
Yes

No

6. How many cigarettes per day do you smoke on average?

SAT

APPENDIX D
Study Costs
This study was supported by a $10,000 grant from the Canadian Tobacco Control
Research Initiative.
Participant Payments:
Screening

$100.00

Baseline questionnaires

$265.00

Intervention #1

$515.00

Breath CO payments (regular)

$1158.00

Breath CO payments (contingencies)

$199.00

Intervention #2

$428.00

Post-study questionnaires

$215.00

Follow-up assessment

$625.00

TOTAL: $3505.00

Equipment:
Saliva cotinine tests

$3642.18

Smokerlyzer mouthpieces

$375.90

TOTAL: $4018.08

$131.69

TOTAL: $387.79

Miscellaneous:
Supplies, etc.

TOTAL GRANT EXPENSES: $7910.87

APPENDIX E
Informed Consent for Study Participation

Research Informed Consent
Title of Study:
Computerized motivational intervention and contingency management for
tobacco smoking in methadone-maintained opiate-dependent individuals
You are being asked to be in a research study of ways to help people who may
want to quit smoking. The study is being conducted at the Jefferson Avenue
Research Clinic, which is affiliated with Wayne State University. Please read this
form and ask any questions you may have before agreeing to be in the study.
The study is being conducted by Heather Durdle, MA, of the Department of
Psychology, University of Windsor and Steven Ondersma, PhD, of Wayne State
University.The funding for this study is being provided by the Canadian Tobacco
Control Research Initiative.
Study Purpose:
The purpose of the study is to understand how your smoking behavior changes
over time. The estimated number of study participants to be enrolled at Wayne
State University is about 60.
Study Procedures:
Participants in this study will be divided into three different groups. The general
procedure for each of these groups is the same. If you take part in the study, you
will be asked to do the following:
You will be asked to complete some initial questionnaires. These will include
questions about yourself and questions related to your use of cigarettes.
Throughout the study, you are free to choose not to answer any of the questions
that are asked of you. These initial questionnaires should take about 20 minutes
of your time and will be completed on an easy-to-use talking computer. You do
not need to know how to use a computer to do any of the computer tasks in this
study.
For the next five weeks, the researcher will meet with you when you come into
the clinic on Monday, Wednesday, and Friday. You will be asked to answer a few
short questions about your use of cigarettes each time. You will also be asked to
provide a sample of your breath carbon monoxide on each of these days. This is
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done by blowing into a cardboard mouthpiece attached to a small carbon
monoxide detector. On one of these days each week (which will be chosen
randomly), you will also be asked to provide a saliva sample. This is done by
placing a small amount of oral fluid into a collection container. This breath
sample and saliva sample will tell us if you have been smoking recently.
Answering these questions and providing these samples should take about five
minutes of your time on each visit.
One week from now, we will ask you to complete a computer task. This will
involve answering some questions and doing some activities that the computer
asks of you. This should take about 20 minutes of your time. Approximately
three weeks later, we will ask you to complete the computer task again. This
should also take you about 20 minutes.
On your last visit at the end of these five weeks, you will be asked to complete
the same questionnaires that you did at the beginning of the study. This should
take about 15 minutes of your time.
Once the study has finished, the researcher will return to the clinic five weeks
later. If you are still attending the clinic, the researcher will ask you to answer
some questions about your use of cigarettes and provide a breath carbon
monoxide sample. These visits should take 20 minutes of your time.
At the beginning and end of the study period and at the follow-ups, the
researcher will access your online medical records on the clinic database. The
researcher will record the results of your urine drug screens that you provide as
part of regular clinic procedures. The results of these urine drug screens will
in no way affect your participation in this study.
Benefits:
There may be no direct benefits for you; however, information for this study may
benefit other people now or in the future. The possible benefits to you for taking
part in this study are that you may decrease the number of cigarettes that you
smoke. Additionally, information from this study may help other people now or in
the future by helping researchers design ways to help people who want to stop
smoking.
Risks:
There may be some minimal risks associated with your participation in this study,
including potential stress. The study investigator will also know about your recent
use of nicotine or illicit substances, which may cause you some embarrassment
or loss of privacy.
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Alternatives:
There are no alternative treatments to not participating in this study. If you
choose not to participate in this research but would like to receive support for
quitting smoking, the investigator can provide you with a list of resources. All
people who enrol in this study will also receive this list of resources.
Research Related Injuries:
In the unlikely event that this research related activity results in an injury, no
reimbursement, compensation or free medical care is offered by Wayne State
University.
If you think that you have suffered a research related injury, let the investigator know
right away.
Study Costs:
There will be no costs to you for participation in this research study.
Compensation:
The amount and type of compensation that you receive will depend on what
group you are randomly assigned to. The investigator will let you know on the
first day of the study what group you are in.
Throughout the study, each time you earn less than $5, you will receive
McDonald's gift certificates. If the amount you earn is $5 or more, you will receive
Target gift cards.
Everyone participating in the study will be compensated in the following ways.
•

For completing the initial questionnaires, you will receive $5 in gift cards.

•

When you complete the two computer tasks, you will receive $10 in gift
cards each time.

•

Once the study period is over, you will receive $5 in gift cards for
completing the same questionnaires that you did at the beginning of the
study.

•

For each follow-up that you participate in, you will receive $15 in gift cards.

For providing breath and saliva samples, Group 1 and Group 2 will be
compensated in the following way:
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•

Over the course of the five-week study, each time that you give us a
sample of breath carbon monoxide and/or saliva and complete the brief
smoking-related questionnaires, you will receive $2 in gift cards.

For providing breath and saliva samples, Group 3 will be compensated in the
following way:
•

For the first week of the study, each time that you give us a sample of
breath carbon monoxide and/or saliva and complete the brief smokingrelated questionnaires, you will receive $2 in gift cards.
For the last four weeks of the study, each time that give us a sample of
breath carbon monoxide and/or saliva and complete the brief smokingrelated questionnaires, you will receive $1 in gift cards. You may also earn
additional gift cards if the samples you provide indicate that you have not
been smoking recently. Both your breath and saliva samples must
show that you have not been smoking in order to earn this payment.
During these four weeks, the first negative sample that you give us will
earn you $4.00. For each time in a row that you give us negative samples,
you will earn an extra 50 cents on top of your last payment. If you give us
a sample that shows you have recently been smoking, you will not earn
anything additional that day and the most you can earn the next day is
reset to $4.00.

If each part of the study is completed, Group 1 and Group 2 will receive a
MAXIMUM of $75 in gift cards. If each part of the study is completed and a
negative breath and saliva sample is provided on each day of the study, Group 3
will earn a MAXIMUM of $141 in gift cards.
Confidentiality:
All information collected about you during the course of this study will be kept
confidential to the extent permitted by law. You will be identified in the research
records by a code name or number. A master list with your identifying information
will be kept in a secured location. Information that identifies you personally will
not be released without your written permission. However, the study sponsor, the
Human Investigation Committee (HIC) at Wayne State University, the Research
Ethics Board (REB) at the University of Windsor or federal agencies with
appropriate regulatory oversight (e.g., Food and Drug Administration [FDA],
Office for Human Research Protections [OHRP], Office of Civil Rights [OCR],
etc.) may review your records.
Any information that you provide (including the results of your breath or
saliva samples) will NOT be shared with your counsellor or any other clinic
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staff. You may, however, choose to tell your counsellor about your involvement
in this study.
A secured master list will match your participant identification number to your
clinic ID. This is so the investigator can access information on your urine drug
screens and other demographic information included in the clinic's computer
system. Because your clinic ID contains your initials and the last four digits of
your social security, you will be asked to complete a separate form to authorize
the researcher to use this information to access the clinic database. Your name
or clinic ID will not be associated with any of the information that you provide.
Personal Health Information (PHI) used and disclosed for the purposes of this
study is protected under the federal regulation know as HIPAA (Health Insurance
Portability and Accountability Act). Your study investigator will discuss with you
your rights under this federal regulation and obtain your authorization to allow the
research team to access your PHI.
Voluntary Participation /Withdrawal:
Taking part in this study is voluntary. You may choose not to take part in this
study, or if you decide to take part, you can change your mind later and withdraw
from the study. You are free to not answer any questions or withdraw at any
time. Your decision will not change any present or future relationships with
Wayne State University or its affiliates or other services you are entitled to
receive.
Your participation in this study is in NO way associated with your
methadone treatment. Although you will be asked to provide breath carbon
monoxide and saliva samples throughout the course of the study, the results of
these samples will not affect your treatment in any way. If you choose to
withdraw from this study, this will not affect your enrolment in the clinic.
Subsequent Use of Data:
It is possible that the data from this research may be used in subsequent studies
to answer a different research question. Your name or other identifying
information will remain confidential. If you do not consent to the further use of
your data, please initial here:
Questions:
If you have any questions now or in the future, or if you think that you need to
report a research related injury, you may contact Dr. Steven Ondersma at (XXX)
XXX-XXX or Heather Durdle at (XXX) XXX-XXX. If you have questions or
concerns about your rights as a research participant, the Chair of the Human
Investigation Committee can be contacted at (XXX) XXX-XXXX.
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Consent to Participate in a Research Study:
To voluntarily agree to take part in this study, you must sign on the line below. If
you choose to take part in this study, you may withdraw at any time. You are not
giving up any of your legal rights by signing this form. Your signature below
indicates that you have read or had read to you this entire consent form,
including the risks and benefits, and have had all of your questions answered.
You will be given a copy of this consent form.

Signature of Participant/Legally Authorized Representative

Date

Printed Name of Participant/ Authorized Representative

Time

"Signature of Witness (When applicable)

Date

Printed Name of Witness

Time

Signature of Person Obtaining Consent

Date

Printed Name of Person Obtaining Consent

Time

APPENDIX F
Quit Smoking Resources:
The following are free smoking cessation resources that are available to you,
should you choose to use them:
Telephone Numbers:
National Network of Tobacco Cessation Quitlines:
1-800-QUIT-NOW
1-800-784-8669
American Cancer Society Quitline:
1-800-ACS-2345
American Lung Association:
1-800-LUNG-USA

Websites:
American Cancer Society:
www.cancer.org
Click on "Guide to quitting smoking"
American Lung Association:
www.lungusa.org
Click on "Tobacco control"
American Heart Association:
www.americanheart.org
Search for "Smoking"

APPENDIX G
Timeline of Study - Payment Schedule
Baseline

Weekl

All participants:

All participants:

Baseline
questionnaires
($5)

Interaction with
computer ($10)

Breath CO and
Tobacco Use and
Beliefs on M/W/F
($2)

Control and CDMI
Groups:
Breath CO and
Tobacco Use and
Beliefs on
M/W/F ($2)
CDMI + CM Group:
Same as above with
payment contingent
on breath CO/saliva
cotinine level
(plus $1)

Week 2

Week 3

Week 4

Control and CDMI
Groups:

Control and CDMI
Groups:

Control and CDMI
Groups:

Breath CO and
Tobacco Use and
Beliefs on M/W/F
($2)

Breath CO and
Tobacco Use and
Beliefs on M/W/F
($2)

Breath CO and
Tobacco Use and
Beliefs on M/W/F
($2)

CDMI + CM Group:
Same as above with
payment contingent
on breath CO/saliva
cotinine level
(plus $1)

CDMI + CM Group:
Same as above with
payment contingent
on breath CO/saliva
cotinine level
(plus $1)

CDMI + CM Group:
Same as above with
payment contingent
on breath CO/saliva
cotinine level
(plus $1)

1 mo. Follow-up
All participants:
Follow-up
questionnaires,
breath CO, saliva
cotinine
($15)

All participants:
Interaction with
computer ($10)
Post-study
questionnaires
($5)

<jj
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APPENDIX H
Details of Brief Computer-Delivered Motivational Intervention
Introduction
Hello, my name is Peedy. We will be working together today.
If it's okay with you, I'd like to spend some time getting to know you better.
Specifically, I'd like to learn a little bit more about your smoking and how you feel right
now about quitting.
You may know that smoking is bad for your health and that it can cause lung disease,
stroke, cancer, and other health problems. Still, many people don't feel that they are ready
to quit. We'll spend some time together today to try and understand how you feel about
your smoking. I'm giving you no pressure to quit. I just met you. You know best what
decision is the right one for you. Sometimes, though, people feel that they are really
ready to quit smoking. If you are one of those people, one of the best things that you can
do is to set a quit date. This is a day, usually within the next two weeks, that you choose
to be the day that you stop smoking. Only you can choose what the best quit date for you
may be.
I'd like to check and see if you feel ready to set a quit date. Don't worry if you're not
ready. Lots of people aren't. Remember, I don't want to pressure you in any way. I will
respect anything that you decide.
Do you feel ready right now to set a quit date?
•
•
a

Yes
No
I'm a little unsure

(on to "Setting a Quit Date")
(on to "Pros and Cons")
(on to "Pros and Cons")

Setting a Quit Date
Sounds like you feel that the best thing for you is to set a quit date. There is a calendar
next to the computer. Take a minute and choose which quit date you would like.
Sometimes the best quit date is one that has a special meaning to you.
What do you choose as your quit date to stop smoking?
(Example)
•
a
a

Monday, July 30th
Tuesday, July 31 st
Wednesday, August 1st
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a
a
•
a
•
a
a
a
a
a
a
a

Thursday, August 2nd
Friday, August 3 rd
Saturday, August 4th
Sunday, August 5th
Monday, August 6th
Tuesday, August 7th
Wednesday, August 8th
Thursday, August 9th
Friday, August 10th
Saturday, August 11th
Sunday, August 12th
None of these dates

(If a quit date is selected, Peedy reflects back the date that was chosen and the participant
moves on to "Plan for Change". If "none of these dates" is selected, then the participant
is taken to "Pros and Cons")
Pros and Cons
It sounds like you plan to keep smoking. At least for a while. I'm sure that you have your
reasons for this. I definitely don't judge you for it and I won't try to force you to change.
I'm just a fat green parrot anyway.
But if it's OK, I'd like to talk with you just a little bit about what you're thinking right
now. No pressure. I just want to help you think about what, if anything, you might want
to change about your smoking.
There can be lots of good and bad things about smoking. Let's think a bit about what
those things are for you.
Here are some positive things about smoking. I know there are lots of options. Take your
time. I am only a bird. I don't have many important places that I need to be.
What are some of the things you like about your smoking?
(Participant chooses all that apply from the list below)
a
a
a
•
a
a
•
a
a

Smoking feels good
Smoking helps me relax and deal with stress
Smoking can be a good way to socialize and bond with other smokers
Smoking makes things more enjoyable
Smoking helps me lose weight or maintain my current weight
I like watching the smoke and the cigarette burn
Smoking keeps away withdrawals
I like taking smoke breaks throughout the day
Something else that is not on this list
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a

None of these options

Now here are some negative things about smoking. I know I asked you some of these
before, but I have a short memory. After all, my brain is only the size of a raisin.
What are some of the things you don't like about your smoking?
a
a
a
a
a
•
a
a
a
a

Smoking costs a lot of money
Smoking affects my health and the functioning of my lungs
Smoking increases my risk of cancer and other diseases
I go through mini-withdrawals from nicotine throughout the day
I am afraid of what smoking is doing to my health or the health of those I love
Smoking makes my face and body look older
Not everyone in my family likes that I smoke
The smell of cigarettes gets in my clothes and hair
Something else that is not on this list
None of these options

Sounds like you feel two ways about your smoking. On the one hand, you've told me that
the good things about your smoking are that (Peedy reflects participant's selections) and
maybe other positive things. But on the other hand, you also feel that the things you don't
like about your smoking are (Peedy reflects participant's selections) and maybe other
negative things.
Everyone is different, but talking about the good and bad things about smoking can get
people thinking.
Overall, how would you rate the effect of smoking on your life?
•
a
a
•

It has no effect at all
It affects a few things
It affects a lot of things
It affects everything in my life

(Participant moves on to "Feedback'')
Feedback
You told me before that you're not interested in changing, and I respect that.
If you ever do start to think about changing though, there are some important things you
might want to know about your smoking.
Most people think this feedback is interesting. I will ask you later what you think of it.
But whether you find it helpful or not, it's all just for you to consider. You can take or
leave as much of it as you want.

117

I know I've asked you this before, you'll have to forgive me. There's that bird's memory
again.
How many cigarettes did you say that you smoke each day?
a
a
a
•
•
a
•
a
a
•
a
a

0-1
2-4
5-7
8-10
11-13
14-16
17-20
21-25
26-30
31-35
36-40
More than 40

Depending on how much you smoke, cigarettes can cost a lot of money.
How much do you think you spend on cigarettes per year?
•
a
a
a
a
a
a
•

Less than $100
$100-$250
$250-$500
$500-$750
$75041000
$1000-$1500
$1500-$2000
$2000 or more

By my estimate, based on the number of cigarettes you smoke each day and the cost of a
pack of cigarettes, you actually spend {calculated amount based on number of cigarettes
smoked per day) each year on cigarettes. Depending on what brand you smoke, it may
cost you even more than this.
That would buy me a lot of bird feed.
What else could you do with the money you spend on cigarettes?
• I could go on a vacation
• I could use it to pay my bills
p I could buy things for my children or grandchildren
a I could buy myself some new clothes or other things that make me happy
a I could buy a new car or start to save for one
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•
a
a
•
•

I could get a new TV or other electronics
I could save it for a rainy day
I could help out someone else financially
Some other reason not listed
None of these options

Here's some trivia for you.
What percent of adults do you think smoke cigarettes?
a
a
a
a
p

a
a
a
a
•

Less than 5%
5% to 10%
10% to 20%
20% to 30%
30% to 40%
40% to 50%
50% to 60%
60% to 70%
70% to 80%
80%) or more

Based on the latest information that I have available to me, I can tell you that 21% of
adult Americans smoke cigarettes. This means that 79% (or 4 out of 5) adults are nonsmokers. {Participant is shown a bar graph of number of smokers versus numbers of nonsmokers).
As you can see from this chart, the number of smokers has been steadily declining over
the past 50 years. {Participant is shown a graph demonstrating a decline in smoking rates
over time).
When we first started today, I asked you about some negative effects of your smoking.
Let's talk about how your score on this questionnaire compares to others {referring to the
Negative Effects of Smoking Questionnaire completed prior to the intervention). Relative
to someone who experiences no negative effects from smoking and someone who
experiences all the negative effects we talked about and gets the maximum score, this is
where your score is. {Peedy demonstrates on a line where the participant's score fell
relative to the minimum and maximum score).
Now let's talk about your breath carbon monoxide (CO) reading. I will give you a little
background on CO first. This is a poisonous gas that in large amounts can be fatal.
Cigarettes produce CO and smokers often breathe in and out this dangerous gas.
What was your breath carbon monoxide reading today?
•
•

0-1
2-3
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• 4-5
a 6-10
a 11-15
• 16-20
• 20-30
a 30-40
a 40 or higher
The average breath carbon monoxide reading for non-smoking adults is around 2. The
amount of carbon monoxide in your breath is (number of multiples higher than a nonsmoker, based on selected CO reading) that of a non-smoker.
That's a lot of information and numbers that I just threw at you. Let's stop for a minute.
I'm curious to know how you're feeling.
What do you make of all that feedback?
a
a
•
•
•
a
•
a
•

I don't really care what feedback I get, it's not going to change me
I don't buy it. I know lots of people who smoke more than I do
I'm not sure I believe it
I don't smoke that much so it's no big deal
It's hard for me to have to face this
I'm shocked. I never knew these things about my smoking
I'm disappointed in myself
I'm feeling a way that's not on this list
I'm not feeling anything

We've just talked a lot about your smoking. I know that you said earlier that you weren't
ready to quit, but sometimes people start to feel a little bit differently.
This little parrot is giving you no pressure to change. You can make your own decisions
about what's best for you. I did want to check in though and see if you might have
changed your mind since the last time I asked you.
Are you thinking now that you'd like to set a quit date to stop smoking?
a
•
a

No
(on to "What would make you decide to quit?")
Yes
(on to ''Setting a Quit Date")
I'm going to keep thinking about it (on to "What would make you decide to
quit?")

Plan for Change
Now that you have decided to stop smoking, let's spend a few minutes making a quit plan
to ensure that you are as successful as possible.

Before we start, there are some important things to know about change. First, change
usually isn't easy. But, second, change can really happen. Most people who commit to
change usually succeed. Third, if you decided you want to change, there are lots of ways
to do it. You just have to find the one that's right for you. For example, getting help with
quitting might be best for some people, but others might prefer to do it on their own.
Fourth, many people who do quit slip a few times at first. They always learn from it. As
long as you never give up, you never fail.
I want to stop and check in with you. You've just told me that you want to quit smoking.
This is a big decision, and it's normal to feel different ways about this.
How are you feeling now that you've decided to quit smoking?
a
•
a
a
a
a
a
•
•
•

Scared
Motivated
Worried I can't do this
Excited
Confused
Nervous
Proud of myself
I'm not really sure yet
Something else not on this list
None of these options

At this point, you might be wondering what you've gotten yourself into. You've told me
that you want to quit, but let me check in with you and see if this is really what you want
to do.
What is the change that you want to make?
a
•

I want to stop smoking cigarettes completely
I want to cut down on the number of cigarettes I smoke

Let's think about why you want to make this change. Everyone has different reasons, but
let's find out what they are for you.
Why do you want to quit smoking?
•
•
a
a
•
a
a
a

To improve my health
To live longer
To make my friends and family proud
Because I deserve to be a non-smoker
To save money
So people stop nagging me
I'm sick and tired of being a smoker
To stop or reverse what smoking has done to me physically

a
a

Something else not on this list
None of these options

An important part of making a change is carefully planning out the steps you want to
take. Everyone has a different plan for quitting. I will ask you about more possible steps
in just a minute.
What are the steps you will take in quitting?
a
•
•
a
•
a

I will throw out my cigarettes and lighters
I will distract myself when I have a craving for a cigarette
I will begin exercising more and drinking lots of water
I will keep track of each cigarette that I smoke
I will stay away from people who smoke or places where there is smoking
None of these options

Here are some more steps to consider.
What are the steps you plan to take in changing?
a
a
•
•
•
a
•
a

I will visit my doctor or talk with my counselor about my smoking
I will write down all the reasons why I want to quit
I will spend more of my time in places where smoking is not allowed
I will break my smoking habits, like having a cigarette when I wake up
I will use a nicotine patch or gum
I will do whatever comes naturally
Something else not on this list
None of these options

Involving other people in your efforts to quit or cut back on smoking can be an important
part of ensuring that you are successful.
What are some of the ways that other people can help you quit smoking?
a They can take my cigarettes from me
a They can quit with me
a They can encourage me to quit
a They can ask how I am doing with quitting
a They can support my efforts to quit
a They can stop smoking around me
a They can distract me when I have a craving
a They can tell me how proud they are of me
a Something else not on this list
a None of these options

You've taken the time to make a quit plan that is the best fit for you. An important part of
making a plan like this is knowing when your plan is working.
How will you know if your plan to quit smoking is working?
a
•
a
•
•
•
•
Q
a
a

If I can go a full day or week without smoking
If I have fewer cravings for cigarettes
If I can cut the number of cigarettes I smoke in at least half
If I begin to feel like a non-smoker
If my breathing and lung functioning improves
If other people notice the changes I am making
If I can walk into a corner store and not buy cigarettes
If I can refuse a cigarette that is offered to me
Something else not on this list
None of these options

When you are making a change, it is also important to plan for things that could interfere
with your goal to quit smoking.
What are some things that could interfere with your goal to quit?
a Being around people who smoke
• If I am going through a very stressful time
• If I find myself feeling depressed or nervous
a If I talk myself out of quitting
• If people pressure me to smoke
a If I slip-up and have a cigarette
a If I decide it's no longer important to quit
a If I don't follow my change plan
a Something else not on the list
a None of the above
Okay. You've just told me a lot of information about your plan to quit smoking. Birds like
me don't have very big brains, so let's see if I've got all this straight. Your quit date is
(Peedy reflects back participant's selections). You're feeling (Peedy reflects back
participant's selections) and maybe some other feelings. All of these are normal reactions
to such a big change. The change goal that you have set for yourself is (Peedy reflects
back participant's selections). You've told me that the reasons you want to change are
(Peedy reflects back participant's selections) and maybe some other reasons too. The
steps you plan to take in changing are (Peedy reflects back participant's selections) or
maybe something else that you feel will be helpful to you.
You've also identified ways that people can help you make this change. You feel that
others can help you by (Peedy reflects back participant's selections) and maybe by doing
something else that you think would be useful to you. You've also shared with me ways
that you will know when your plan is working. You will know if your plan to quit or cut
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back on smoking is working if (Peedy reflects back participant's selections) or maybe
something else. You also took the time to think about what might interfere with your plan
to change. You feel that things that could interfere are (Peedy reflects back participant's
selections) or maybe there is something else that could interfere with your goal.
Before we finish up, I want to check in again and see how you're feeling. You came up
with quite a plan for change, and I want to see what you think of it.
How are you feeling after hearing your plan for change?
•
a
•
•
a
a
a
a
a
•

Eager to put my plan into action
Worried I can't do it
Excited to try it
Scared it will be hard
Doubting I can do this
It sounds overwhelming
I think it was helpful to have done this
Hopeful that this will work for me
Something else not on this list
None of these options

(Participant proceeds to "Goodbye")
What would make you decide to quit?
I hear you telling me that you plan to keep on smoking. That's your decision to make, and
I don't judge you for it. Thanks for being so honest with me.
Before we finish, I'd like to find out what you feel might make you think more about
quitting in the future.
What would make you think more about quitting?
a
a
•
a
•
•
•
a
Q
•

If I finally get tired of what smoking is doing to me
If my doctor tells me I have to
If someone I know gets sick or dies from smoking
If someone I care about asks me to quit
If I think more about the negative aspects of smoking
If I develop a health problem from smoking
I might just wake up one morning and decide to quit
Nothing could make me want to quit
Something else not on the list
None of these options

So you might consider quitting smoking (Peedy reflects back participant's selections) or
maybe if something else happens in the future. Sounds like you know how important it
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can be to keep an eye on your smoking and check in with yourself on whether you may
want to quit.
Goodbye
Thank you for sharing your thoughts with me. That's all for today.
Have a nice day!
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APPENDIX I
Details of Control Intervention
Introduction
Hello, my name is Peedy. We will be working together today.
If it's okay with you, I'd like to spend some time today getting to know you better.
Specifically, I will be asking you a little bit about your likes and dislikes when it comes
to music and television.
We'll also have the chance to watch some brief music videos and clips from television
shows.
I will begin by asking you some questions to learn more about your tastes in music.
Here are some R & B artists. There definitely is a lot of talent amongst these musicians.
Which of these artists do you like to listen to?
•
a
•
a
a
a
a

Aretha Franklin
Ray Charles
Stevie Wonder
Little Richard
The Supremes
Someone else not on this list
None of these options

Now here are some rock artists. Some of these bands can really put on a good show.
Which of these artists do you like to listen to?
a U2
a Nickelback
a Aerosmith
a Coldplay
• Red Hot Chili Peppers
a Someone else not on this list
a None of these options
Here are some heavy metal artists. You may or may not have heard of all of them.
Which of these artists do you like to listen to?
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•
•
a
a
•
•
•

Metallica
Iron Maiden
Korn
Led Zeplin
ACDC
Someone else not on this list
None of these options

Now here are some jazz musicians. I really enjoy listening to some good jazz music.
Which of these artists do you like to listen to?
a
•
•
a
•
•
•

Diana Krall
Louis Armstrong
Nat King Cole
Miles Davis
Duke Ellington
Someone else not on this list
None of these options

I hear you telling me that you like a lot of different musicians and types of music. So far
you have said that you like (Peedy reflects back participant's selections) and maybe some
other artists that weren't listed.
Here are some rap artists. I like a lot of these guys but sometimes they use language that a
bird like me can't handle.
Which of these artists do you like to listen to?
• Eminem
• Snoop Dogg
a 50 Cent
• Diddy
a JayZ
a Someone else not on this list
a None of these options
Now here are some classical musicians.
Which of these artists do you like to listen to?
a
•
a
a
•

Beethoven
Mozart
Bach
Schuman
Ernst

a
a

Someone else not on this list
None of these options

Here are some pop musicians or groups. I like to dance to this music sometimes.
Which of these artists do you like to listen to?
a
a
a
Q
a
a
a

Justin Timberlake
Britney Spears
Black Eyed Peas
Madonna
Kelly Clarkson
Someone else not on this list
None of these options

Here are some country musicians. I like this music, but sometimes the songs are kind of
sad.
Which of these artists do you like to listen to?
•
•
•
a
a
a
a

Kenny Chesney
Carrie Underwood
Johnny Cash
Tim McGraw
Garth Brooks
Someone else not on this list
None of these options

You have told me that you like a lot of different types of music. You just said that you
like (Peedy reflects back participant's selections) and maybe some other artists that
weren't on the list of options.
Now here's the fun part. I have some music clips for us to watch.
Which one of these videos would you like to see?
a
•
•

Ring of Fire (Johnny Cash)
What a Wonderful World (Louis Armstrong)
Signed Sealed Delivered (Stevie Wonder and Beyonce)

(Participant selects and watches a 2 minute video clip).
That was good, wasn't it?
Now let's talk about some television shows that you like.
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First, I want to ask you a bit about how much television you watch.
On average, how many hours of television do you watch each day?
a
•
•
•
a
a
•
a

I never watch television
Less than 30 minutes
30 minutes - 1 hour
1-2 hours
2-4 hours
4-6 hours
6-10 hours
More than 10 hours

By my calculations, this means that you spend (number of hours based on participant's
selection) hours per week, or (number of hours based on participant's selection) hours
per year watching television.
Do you ever wonder about how the amount of television you watch compares to others?
How many hours a day do you think the average adult watches television?
a
a
a
a
a
•
a

Less than 30 minutes
30 minutes to 1 hour
1-2 hours
2-4 hours
4-6 hours
6-10 hours
More than 10 hours

According to the latest statistics, the average American adult watches four and a half
hours of television a day. This equals sixteen hundred and forty two hours a year, or sixty
eight full days.
A few hours can really add up. I'm curious to know how you're feeling about the amount
of television that you watch.
Do you think you watch too much television?
a
a
a

No
Yes, I should really cut back
Yes, but I'm going to continue watching it as much as I do

Now let's talk about what television shows you enjoy watching.
Here are some reality television shows.
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Which of these shows do you like to watch?
•
a
a
a
a
a
a

Survivor
Big Brother
America's Next Top Model
The Real World
American Idol
Something else not on the list
None of these options

Here are some legal or crime shows. There sure are a lot of spin-offs of these shows,
aren't there?
Which of these shows do you enjoy watching?
•
a
•
•
•
a
a

Law and Order
Law and Order: SVU
CSI
CSI: Miami
CSI: New York
Something else not on this list
None of these options

Now here are some game shows. Did you know that Bob Barker is retiring after hosting
the Price is Right for 35 years?
Which of these shows do you like to watch?
• Jeopardy
a Wheel of Fortune
a Price is Right
a Deal or No Deal
a 1 vs. 100
a Something else not on this list
a None of these options
I hear you telling me that you like watching a lot of different shows. So far you have said
that you like (Peedy reflects back participant's selections) and maybe something else that
was not on the list of options.
Let's find out what other television shows you like.
Here are some medical shows that are on television. Did you know that ER is now in its
13th season?
Which of these shows do you like to watch?

•
•
•
a
a
a
a

ER
Grey's Anatomy
House
Scrubs
Nip/Tuck
Something else not on the list
None of these options

Now here are some talk shows. Did you know that Oprah has signed on to do her show
until two thousand and eleven? That will be 25 years on the air.
Which of these shows do you like to watch?
a
•
•
•
a
•
•

Oprah
Tyra Banks
Maury Povich
Dr. Phil
Regis and Kelly
Something else not on the list
None of these options

Here are some comedy shows. Some of these really make me laugh.
Which of these shows do you like to watch?
a
a
a
•
•
a
a

Seinfeld
Fresh Prince of Bel-Air
Friends
Everybody Hates Chris
Family Guy
Something else not on the list
None of these options

You have told me that you like different types of shows. You have said that you like
(Peedy reflects back participant's selections) and maybe some other shows that weren't
listed.
The fun part again. I have a few clips from television shows that we can watch.
Which one of these clips would you like to see?
•
a
•

Deal or No Deal
Seinfeld (Elaine Dancing)
Fresh Prince of Bel-Air (Carlton Dancing)

(Participant selects and watches a 2 minute video clip).
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Thank you for sharing your thoughts with me. That's all for today.
Have a nice day!
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APPENDIX J
Demographics Questionnaire
1. Gender:

Male

Female

2. Age:

3. Ethnicity: African American

Caucasian

Other

4. What is the highest level of education you have obtained?
Less than High School (please indicate which grade:

)

GED
College/University
5. Are you currently employed?

Yes

(Full time or Part time:

No

6. Please estimate your average income each month, from all sources:
Less than $500
$501 -$1000
$1001 -$1500
$1501 -$2000
$2001 - $2500
More than $2500

)
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APPENDIX K
Smoking Background Questionnaire
1. How old were you when you smoked your first cigarette?

2. How old were you when you started smoking regularly (three times a week or
more)?

3. How many YEARS in total would you say that you have smoked cigarettes?

4. How many times in your life have you tried to quit smoking?

5. What is the longest period of time that you have gone without smoking?

6. Have you ever talked to your counsellor at the clinic about quitting smoking?

7. How much money each WEEK do you generally spend on cigarettes?

8. How many cigarettes do you generally smoke each day?

9. What ways have you tried to quit smoking? (Check all that apply)
• On my own ("cold-turkey")
• Nicotine patches
• Nicotine gum
• Medication prescribed by a doctor (e.g., buproprion / Wellbutrin / Zyban)
D Hypnosis or acupuncture
a Other:
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APPENDIX L
Timeline Followback
(Sobell & Sobell, 1996)
Instructions:
We would like you to recall what your cigarette use was like in the past
month. This is not a difficult task when you use a calendar like the one below. As
you can see, this calendar has important holidays marked on it. Take a moment
to also write in your own personal holidays and events. These may include
birthdays, trips, sporting events, or celebrations.
Now, go through the calendar and write down how many cigarettes you
smoked on each of the days. We want you to be as accurate as possible,
although we know it is hard for anyone to recall things with 100% accuracy. You
may also think about things like whether you tend to smoke more on the
weekends, or if there were any days you didn't have cigarettes, went without
them by choice, or if you were feeling sick and didn't smoke as much on certain
days.
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(Researcher marks the past 30 days on the calendar)

JANUARY/FEBRUARY
SUN

MON

TUES

WED

THURS

FRI

SAT

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

M. Luther
King Jr. Day

21

22

23

24

25

26

27

28

29

30

31

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

22

23

24

Valentine's
Day

18

19

20

21

27

28

President's
Day

25

26

APPENDIX M
Brief Tobacco Quantity Assessment

(Monday version)
How many cigarettes did you smoke yesterday (Sunday)?
How many cigarettes did you smoke the day before yesterday (Saturday)?

How many cigarettes did you smoke three days ago (Friday)?

(Wednesday version)
How many cigarettes did you smoke yesterday (Tuesday)?
How many cigarettes did you smoke the day before yesterday (Monday)?

(Friday version)
How many cigarettes did you smoke yesterday (Thursday)?
How many cigarettes did you smoke the day before yesterday (Wednesday)?

APPENDIX N
Tobacco Use and Beliefs Measure

How MOTIVATED are you to quit smoking?

Not at all

Extremely

How CONFIDENT are you that you would be able to quit smoking
if you wanted to?

Not at all

Extremely
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APPENDIX O
Fagerstrom Test for Nicotine Dependence
(Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991)
1. How soon after you wake up do you smoke your first cigarette?
D After 60 minutes
• 31-60 minutes
• 6-30 minutes
• Within 5 minutes
2. Do you find it difficult to refrain from smoking in places where it is forbidden?
D No
D Yes

3. Which cigarette would you hate most to give up?
• The first in the morning
• Any other

4. How many cigarettes per day do you smoke?
D 10 or less

• 11-20
• 21-30
• 31 or more
5. Do you smoke more frequently during the first hours after awakening than
during the rest of the day?
• No
D Yes
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6. Do you smoke even if you are so ill that you are in bed most of the day?
• No
D Yes
Scoring:
0-2

Very low dependence

3-4

Low dependence

5

Medium dependence

6-7

High dependence

8-10 Very high dependence
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APPENDIX P

Fairly sure

Absolutely sure

0

2

3

4

2. When I have a drink with friends

0

2

3

4

3. When I feel depressed

0

2

3

4

4. When celebrating something

0

2

3

4

5. When I am angry

0

2

3

4

6. When drinking wine, beer, or other spirits

0

2

3

4

7. When I feel very anxious

0

2

3

4

8. When I am with smokers

0

2

3

4

9. When I want to think about a difficult problem

0

2

3

4

10. After a meal

0

2

3

4

11. When I feel the urge to smoke

0

2

3

4

0

2

3

4

12. When having coffee or tea

Not very sure

1. When I feel nervous

The following are situations in which certain people
might be tempted to smoke. Please indicate whether
vou are sure vou could refrain from smokinq in each
situation.

Not at all sure

More or less sure

Smoking Self-Efficacy Questionnaire-!2 (Etter, Bergman, Humair, & Perneger, 2000)
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Subscales:
Odd items: Internal stimuli subscale
Even items: External stimuli subscale
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APPENDIX Q

-1

0

2

2. I am trying to smoke less than I used to (A)

-2

-1

0

2

3.1 enjoy smoking but sometimes I smoke too much

-2

-1

0

2

4. Sometimes I think I should cut down on my
smoking (C)

-2

-1

0

2

5. It's a waste of time thinking about my smoking (P)

-2

-1

0

2

6. I have just recently changed my smoking habits
(A)

-2

-1

0

2

7. Anyone can talk about wanting to do something
about smoking, but I am actually doing something

-2

-1

0

2

8.1 am at the stage where I should think about
smoking less (C)

-2

-1

0

2

9. My smoking is a problem sometimes (C)

-2

-1

0

2

10. There is no need for me to think about changing
my smoking (P)

-2

-1

0

2

11.1 am actually changing my smoking habits right
now (A)

-2

-1

0

2

Agree

-2

Strongly
Agree

Unsure

1.1 don't think I smoke too much (P)

Below are a list of ways that people may feel
about their smoking. Please circle the response
that best suits you for each item.

Strongly
Disagree

Disagree

Readiness to Change Questionnaire (Rollnick, Heather, Gold, & Hall, 1992)
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12. Smoking less cigarettes would be pointless for
me(P)

Subscales:
P = Precontemplation
C = Contemplation
A = Action

-2

-1

0

1

2
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APPENDIX R
Stage of Change Algorithm (DiClemente et al., 1991)

Are you seriously thinking of quitting smoking?
•

Yes, within the next 30 days
o

If Yes: In the last year, how many times have you quit smoking for at least
24 hours? (PREPARATION STAGE if they have one 24-hour quit attempt
in the past year. If no quit attempt then CONTEMPLATION STAGE)

•

Yes, within the next 6 months (CONTEMPLATION STAGE)

•

No, not thinking of quitting (PRECONTEMPLATION STAGE)

•

I have already quit smoking (ACTION / MAINTENANCE)
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APPENDIX S

Not at all

A little

Somewhat

Very much

Negative Effects of Smoking Questionnaire

1.1 have been unhappy because of my cigarette smoking

0

1

2

3

2.1 have felt guilty or ashamed because of my cigarette
smoking

0

1

2

3

3.1 feel out of breath if I walk up a flight of stairs

0

1

2

3

4. My physical health has been harmed by cigarette smoking

0

1

2

3

5.1 often have a cough that I can't get rid of

0

1

2

3

6.1 worry that I am killing myself by smoking cigarettes

0

1

2

3

7.1 am more at risk of developing lung, throat, or mouth
cancer because of my cigarette smoking

0

1

2

3

8.1 am more at risk of having a heart attack or stroke because
of my cigarette smoking

0

1

2

3

9.1 get very anxious, irritable, or moody when I can't have a
cigarette

0

1

2

3

10.1 find myself craving a cigarette when I have not had one
in awhile

0

1

2

3

Below are a list of negative effects smoking can have on
someone. Please indicate to what extent each of these may
have happened to you in the past 30 days.
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11. My clothes, house, or car smell like cigarettes

0

2

3

12. My physical appearance has been harmed by my smoking

0

2

3

13. My breath often smells from smoking

0

2

3

14. My fingers, teeth, or skin are yellow from smoking

0

2

3

15. My skin is dry and my hair is brittle from smoking

0

2

3

16.1 am fearful that the ones I love may be negatively affected
by my cigarette smoking

0

2

3

17. A friendship or close relationship has been damaged by
my cigarette smoking

0

2

3

18. My partner and I argue about my cigarette smoking

0

2

3

19. My smoking has damaged my social life, popularity, or
reputation

0

2

3

20.1 have spent too much money on cigarettes

0

2

3

Scoring = total on all items
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APPENDIX T
Attributes of Treatment Measure

Agree

2

3

4

5

2. ...focused on things that were relevant to me

2

3

4

5

3. ...was something that I would recommend

2

3

4

5

4. ...didn't do much for me (R)

2

3

4

5

5. ...was accepting

2

3

4

5

6. ...made me want to change

2

3

4

5

7. ...was understanding

2

3

4

5

8. ...was respectful of me

2

3

4

5

9. ...was unsupportive (R)

2

3

4

5

10...was enjoyable

2

3

4

5

11...was annoying (R)

2

3

4

5

12...made it worthwhile to change for a little bit (R)

2

3

4

5

Strongly
Agree

Unsure

1. ...was helpful

The treatment that 1 got...

Strongly
Disagree

Disagree

Be low are a list of ways people might feel about
The treatment that they received in this study.
Please circle the response that best suits you for
each item.
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R = reverse scored items
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APPENDIX U

Unsure

Agree

1. I didn't have any choice (E)

2

3

4

5

2. I got paid for doing it (E)

2

3

4

5

3. It is something I was interested in doing (I)

2

3

4

5

4. It is good for my health (I)

2

3

4

5

5. I was supposed to do it (E)

2

3

4

5

6.1 wanted to do it for myself (I)

2

3

4

5

7.1 didn't want to disappoint the researcher (E)

2

3

4

5

8. It made me feel good about myself (I)

2

3

4

5

9.1 knew I was being monitored (E)

2

3

4

5

10. It was a goal I had set for myself (I)

2

3

4

5

E =External motivation subscale
I = Internal motivation subscale

Strongly
Agree

Disagree

Be low are a list of reasons that people may give
for changing or trying to change their smoking
behaviour. Please think about how each reason
fits for you during your participation in this study
and circle the best response.

Strongly
Disagree

Motivation for Change Questionnaire
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APPENDIX V

Very true

The reason I tried to quit or cut back on
Smoking is...

Not at all true

The following questions relate to the
reasons why you might have tried to quit
or cut back on smoking over the course
of this study. Different people have
different reasons for doing that, and we
want to know how true each of the
following reasons are for you

Somewhat true

Treatment Self-Regulation Questionnaire (Williams, Freedman, & Deci, 1998)

1. Because I felt I wanted to take
responsibility for my own health (A)

1

2

3

4

5

6

7

2. Because I felt guilty or ashamed of
myself (C)

1

2

3

4

5

6

7

3. Because I personally believed it was
the best thing for my health (A)

1

2

3

4

5

6

7

4. Because others would be upset with
me if I smoked (C)

1

2

3

4

5

6

7

5. I really didn't think about it (AM)

1

2

3

4

5

6

7

6. Because I thought carefully about it
and believe it is very important for
many aspects of my health (A)

1

2

3

4

5

6

7

7. Because I would have felt bad about
myself if I had smoked (C)

1

2

3

4

5

6

7

Very true

Somewhat true

The reason 1 tried to cut or quit back on
smoking is...

Not at all true
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8. Because it is an important choice 1
really wanted to make (A)

1

2

3

4

5

6

7

9. Because it was easier to do what 1 am
told than to think about it (C)

1

2

3

4

5

6

7

10. Because I felt pressure from others not
to smoke (AM)

1

2

3

4

5

6

7

11. Because it was consistent with my life
goals (A)

1

2

3

4

5

6

7

12. Because I wanted others to approve of
(C)

1

2

3

4

5

6

7

13. Because it was very important for being
healthy as possible (A)

1

2

3

4

5

6

7

14. Because I wanted others to see that I
could do it (C)

1

2

3

4

5

6

7

15. I don't really know why (AM)

1

2

3

4

5

6

7

A = Autonomous response items
C = Controlled response items
AM = Amotivational response items

APPENDIX W
Additional Analysis of Breath CO Results
Consecutive breath CO samples in non-smoker range
The number of consecutive days breath CO was in the non-smoking range was
compared (Figure 13). Statistical analysis of these data (a univariate ANCOVA with
number of samples in the non-smoker range during the baseline week as the covariate)
revealed a significant difference between the groups, F(2,33) = 3.94,p = .03, n p =.19.
Further analysis (Fisher's LSD post-hocs) indicated that the CDMI plus CM group had
significantly more non-smoking days in a row than the control group (Mean Difference =
.25, p = .01). The number of consecutive non-smoking days by the CDMI only group did
not significantly differ from the control (Mean Difference = .11,/? = .20) or the CDMI
plus CM group (Mean Difference = -.14, p = .13).
Two group comparisons were run and partial eta-squared was used to calculate
Cohen's d. These results revealed a large advantage for CDMI only (d= 1.13) and CDMI
plus CM (d=l.\0)

over the control group. A moderate effect for the magnitude of the

difference between CDMI only and CDMI plus CM was also found (d = .52), with the
CDMI plus CM group producing more consecutive days in the non-smoking range.

Breath CO reductions of 25% relative to baseline
An analysis was done on the number of breath CO samples reduced 25% relative
to baseline (Figure 14). A statistical analysis of these data (a univariate ANOVA)
indicated a significant difference between the groups, F(2,34) = 3.63,/? = .04, r|2p =.18.
Further analyses (Fisher's LSD post-hocs) revealed that the CDMI plus CM group had

9 -,
8
7 6 5
4
3
2

Control

CDMI only

CDMI plus CM

Figure 13. Number of consecutive breath CO samples in the non-smoker range across
the study period.

significantly more days where breath CO was reduced by 25% than the control group
(Mean Difference = -3.54, p = .01). The difference between the CDMI only and CDMI
plus CM group was a non- significant trend (Mean Difference = 1.44, p = .07). No
significant difference was found between the control and CDMI only group (Mean
Difference = . 83, p = . 55).
Effect size estimates revealed a large magnitude of effect when CDMI plus CM
was compared to control (d = 1.08) and CDMI only (d = .89), with the CM group
producing more samples that were reduced by 25% relative to baseline. A moderate
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Figure 14. Number of days during the study period that breath CO was reduced by 25%
relative to baseline.

effect was found between the control and CDMI only group (d = .54), with the control
group producing the fewest number of samples that met this criterion.
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APPENDIX X
Results for Fagerstrom Test for Nicotine Dependence
Overall Fagerstrom scores for all participants were in the low to moderate range
of nicotine dependence. These scores showed some small variations from baseline to
post-study. At follow-up, the Fagerstrom scores had increased to at or above baseline
values for the CDMI only and control group (Figure 15). The CDMI plus CM group
showed a small decrease relative to both baseline and post-study.

Summary of Fagerstrom findings
These results suggest that there was no difference in Fagerstrom scores between
the groups, either at post-study or follow-up.

Baseline versus post-treatment
Change scores (post-study minus baseline scores) were essentially the same
across the three groups, F(2,34) = .04, p = .96, \]2P =.00.

Baseline versus follow-up
Fagerstrom scores at follow-up were also compared (controlling for baseline
scores). No significant difference was found between the groups, F(2,33) = .17, p = .47,
n 2 P =.04.
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Figure 15. Fagerstrom Test of Nicotine Dependence scores across baseline, post-study
and follow-up.
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APPENDIX Y
Results for Smoking Self-Efficacy Questionnaire-12
Internal subscale
Across all participants, the internal motivation subscale scores were in the low to
moderate possible range of scores for this measure. Overall internal subscale scores for
all participants showed a small increase between baseline and post-study. This increase
was maintained at follow-up. When the groups were examined separately, only the CDMI
only group showed a steady increase in internal self-efficacy across post-study and
follow-up (Figure 16). The other two groups were highest at post-study and decreased at
follow-up.

Summary of internal subscale findings
These results indicate that there were no significant differences between the
groups on the internal subscale scores, either at post-study or follow-up.

Baseline versus post-study
Change scores were calculated for each of the groups on the post-study internal
subscale values, taking into account baseline values. No significant differences were
found, F(2,34) = .16,p = .85, r|2p = 01.

Baseline versus follow-up
Similar scores were calculated for the follow-up values, controlling for baseline
scores. No significant group differences were found, F(2,33) = .13,p = .49, n2p =.04.
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Figure 16. Smoking Self-Efficacy Internal Subscale scores across baseline, post-study
and follow-up.

External subscale
The external scores were in the low to moderate range and remained relatively
constant across time for all three groups across post-study and follow-up (Figure 17).

Summary of external subscale findings

These results indicate that there were no significant differences between the
groups on the external subscale scores, either at post-study or follow-up.
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Figure 17. Smoking Self-Efficacy External Subscale scores across baseline, post-study
and follow-up.

Baseline versus post-study
Statistical analysis of the post-study external subscale scores (minus baseline
scores) showed that the level of change across the three groups did not differ, F(2,34) =
.05,/?=.95,r| 2 p = 00.

Baseline versus follow-up
Similarly, no difference was found on follow-up scores (controlling for baseline
values), F(2,33) = .05,/? = .95, n2p =.00.

APPENDIX Z
Results for Readiness to Change Questionnaire
An analysis of the Readiness to Change stage scores across all participants
showed that at baseline, post-study, and follow-up, approximately two thirds of the
participants were in the contemplation stage of change (Table 7). This suggests that
throughout the study, the majority of participants were considering making a change in
their smoking but had not yet progressed to the action stage. The percentage of
participants in the preparation stage of change appeared particularly stable for the
combined intervention group, CDMI plus CM, while the other two groups showed a
slightly larger degree of progression through the stages of change.
There were no statistically significant group differences in stage of change at
baseline, %2(4) = 4.90,p = .30; post-study, x2(4) = 1.49,/? = .83; or follow-up, ^(6) =
6.42,/? = .38.

Table 7
Percentage of participants in each stage of change (Readiness to Change Questionnaire
scores)
Control

CDMI only

CDMI plus CM

Baseline
Precontemplation
Contemplation
Action

0
85.7
7.1

0
90.9
9.1

16.7
66.7
16.7

7.1
78.6
14.3

0
72.7
27.3

8.5
75.0
16.7

7.1
64.3
21.4

18.2
63.6
18.2

8.3
75.0
16.7

Post-study
Precontemplation
Contemplation
Action
Follow-up
Precontemplation
Contemplation
Action
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APPENDIX AA
Results for Stages of Change Algorithm
Across all three groups, approximately three quarters of participants were in the
contemplation stage at baseline. At post-study and follow-up, approximately half of the
participants remained in the contemplation stage, while one third to one quarter had
progressed to the preparation stage of change (Table 8).
There were no group differences in stage of change at baseline, %2(4) = 2.10, p =
.72; post-study, tf(6) = 6.42, p = .38; or follow-up, x2(4) = .97, p = .92.

Table 8
Percentage of participants in each stage of change (Stages of Change Algorithm)
Control

CDMI only

CDMI plus CM

7.1
85.7
7.1
0

9.1
81.8
9.1
0

25.0
66.7
8.3
0

14.3
57.1
28.6
0

0
54.5
45.5
0

25
50.0
16.7
8.3

21.4
64.3
7.1
0

18.2
45.5
36.4
0

25.0
33.3
33.3
8.3

Baseline
Precontemplation
Contemplation
Preparation
Action/Maintenance
Post-study
Precontemplation
Contemplation
Preparation
Action/Maintenance
Follow-up
Precontemplation
Contemplation
Preparation
Action/Maintenance
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APPENDIX AB
Results for Illicit Drug Use
Urine drug information from each of the participants was recorded for the period
five weeks prior to the study (pre-study), the four weeks of the study period plus baseline
week (study period), and the five weeks between the end of the study period and followup (post-study). These drug screens were provided randomly as part of regular clinic
procedures; therefore the number of drug screens was different for each participant. To
ensure these comparisons were equivalent, the percentage of positive screens of those
provided during each of these time points was calculated for each participant.

Opiates
Across all participants, rates of illicit opiate use were relatively moderate (average
of 43.2% pre-study and 32.2% at post-study). This use progressively decreased from prestudy, to study period, to post-study. Looking at each group separately, each of the three
groups decreased their opiate use during the study period relative to pre-study (Figure
18). The CDMI and CDMI plus CM groups continued this reduction to post-study, while
opiate use increased (although not to baseline levels) for the control group at follow-up.

Summary of findings for opiate use
No differences were found between the groups on opiate use during the study
period or at post-study.

50
45
40
35

Control
CDMIonly

30

-A-CDMIplusCM

25
20

15
Pre-study

Study Period

Post-study

Figure 18. Percentage of opiate positive urine drug screens across the 5-weeks pre-study,
the 5-week study period, and 5-weeks post-study.

Study period versus pre-study
In order to calculate Cohen's d as a measure of effect size, change scores were
calculated for the percentage of urine drug screens positive for opiates during the study,
minus the percentage that were positive prior to the study. These scores were not
significant with a univariate ANOVA, F(2,29) = .33,p = .72, r\\ =.02.

Post-study versus pre-study
Change scores for opiate use at post-study (minus baseline use), did not show
differential reductions between the three groups, F(2,28) = .18,/? = .84, n2p =.01.
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Cocaine
Overall rates of cocaine use were relatively moderate (34.8% at pre-study and
26.9% at post-study). The overall rate of cocaine use across the three groups showed a
reduction across the three time points. Control participants maintained their rate of use
from pre-study through the study period, and then increased their use post-study (Figure
19). The two groups that received the CDMI showed reductions in cocaine use across
each of the three time points. This reduction was most apparent for the combined CDMI
and CM group, who reduced their cocaine use by more than half from pre-study to poststudy.

Summary of results for cocaine use
Effect size estimates suggest that CDMI plus CM was the most efficacious in
producing reduced levels of cocaine use post-study, relative to pre-study. No differences
between the groups were found during the study period, relative to pre-study.

Study period versus pre-study
Rates of cocaine use during the study period (minus pre-study rates of use) were
compared and no significant difference between the groups was found, F(2,28) = .72, p =
.50, n2p =.05.
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Figure 19. Percentage of cocaine positive urine drug screens across the 5-weeks prestudy, the 5-week study period, and 5-weeks post-study.

Post-study versus pre-study
A comparison of the change scores from pre-study to post-study found a nonsignificant trend (p < .30) in the difference between the groups, F(2,27) = 1.89,/? = .17,
r)2p =.12. Effect sizes revealed that relative to the control group (which increased their
rates of cocaine use over this time), the CDMI only group showed a moderate advantage
in reducing cocaine use (d = .53), while this advantage was large for the CDMI plus CM
(d= .81). The combined intervention of CDMI plus CM showed a small to moderate
magnitude of effect size over CDMI only (d= .35).
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APPENDIX AC
Notable Participant Characteristics
It was initially desired to examine the effect of ethnicity on study variables, as
previous work has found larger effects of MI on minority participants relative to
Caucasian samples (Hettema et al., 2005). Due to the low number of Caucasian
participants in our study sample (N = 4), these analyses could not be done. Further
complicating this was the fact that all four Caucasian participants were female, and all
had recently given birth or gave birth during the study period (as this particular clinic was
running a program for pregnant women on methadone). One additional African American
woman was also a new mother. Research has shown that it is particularly hard to affect
substance use-related change in pregnant and post-partum women who continue to use
during their pregnancy (e.g., Ondersma et al., 2005; Ondersma et al., 2007). This is
primarily due to the fact that women who do not quit smoking or using drugs when they
first become pregnant are not likely to quit during the pre- and post-partum period.
While analysis of these factors is beyond the scope of this dissertation, informal
comparisons between these Caucasian mothers and African American participants across
all three study groups reveals a very interesting pattern of results. While the Caucasian
mothers demonstrated higher (and increased over time) levels of breath CO, saliva
cotinine, and self-reported number of cigarettes relative to African American participants,
their self-reported level of motivation was much higher. Therefore, while their motivation
was high, their efficacy to stop smoking was low. Their overall acceptability of the
interventions offered to them in this study (as measured by the Attributes of Treatment
Measure), while still relatively high, was also significantly lower (M= 3.45, SD = .39)

than that of African American participants (M= 3.99, SD = .36), F(l,32) = 7.51,;? = .01,
n 2 p =19.
It is not known whether these observed differences are due to effects of ethnicity,
pre- and post-natal factors, or even gender. This is an interesting area of investigation,
and future research with adequate sample sizes is needed to tease apart these effects.
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